Proprie tary and Confidential  CLINICAL TRIAL PROTOCOL 
A Phase 2, Double-blind, Placebo -Controlled S tudy to Investigate 
the Efficacy, Safety 
and Tolerability of MRG-2 01 Following 
Intradermal Injection in 
Subjects with a History of Keloids  
Protocol Nu
mber:  MRG201-30-2 01
([STUDY_ID_REMOVED])  
Version 1.0, Final 
16 March 2018 
miRagen
 Therapeutics, Inc. 
6200 Lookout Road 
Boulder, CO  80301 
CONFIDENTIALITY STAT EMENT  
The infor mation  contained  in this protocol is provided to you in confidence, for review  by yo u, your 
staff,  and any applicable  regulato ry authority or institutional  review comm ittee.  It is understood that 
this infor mation  may not be disclosed  to any other  party, in any form, without pr ior written 
authorization from miRagen  Therapeutics, Inc. except to the extent  necessary  to obtain  infor med 
consent  from  the persons to whom the study drug m ay be administered. 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 2 of 100 STATEMENT OF COMPLIA NCE  
This study will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, and clinical research guidelines established by the United States 
Code of Federal Regulations ( 21 CFR Parts 50, 56, and 312) and the International Conference on 
Harmonization (ICH) E6(R1) Guideline for Good Clinical Practice (GCP).   
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 4 of 100 INVESTIGATOR AGREEME NT 
I confirm that I have read and understand this protocol, the Investigator’s Brochure, and any 
other product information provided by the Sponsor, and agree to the following: 
•To conduct this trial in accordance with the design and provisions of this protocol;
•To await Institutional Review Board ( IRB) approval for the protocol and informed
consent document before initiating enrollment into the study ;
•To ensure that the requirements for obtaining informed consent are met and to obtaininformed consent from subjects before t heir enrollment into the study ;
•To provide sufficient and accurate financial disclosure and to update this information if
any relevant changes occur during the investigation and for one year following thecompletion of the study;
•To collect and record data as required by this protocol into the case report form;
•To maintain the confidentiality of all information received or developed in connectionwith this protocol;
•To conduct this trial in accordance with the ICH GCP, the Declaration of Helsinki, andappli cable regulatory requirements ;
•To permit trial-related monitoring, audits, IRB review, and regulatory inspection(s) byproviding direct access to source data/documents;
•To prepare annual, final and safety  reports as required by this protocol and by regulation
under 21 CFR 312.64;
•To maintain study documentation for the period of time required as stipulated in the
protocol;
•To report all adverse events to miRagen Therapeutics, Inc. within the timeframe
specified ;
•To report all serious adverse events within 2 4 hours after becoming aware of the event as
directed in the protocol;
•To comply with the provisions of the Clinical Trial Agreement to which I will be a
signatory, including but not limited to , the disclosure or publication of data collected
during this t rial, as stipulated  in that agreement.
Signature of  Investigator Date  
Investigator Name (print or type) Site Number  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 5 of 100 TABLE OF CONTENTS  
STATEMENT OF COMPLIANCE .............................................................................................2 
PROTOCOL APPROVAL PAGE ...............................................................................................3 
INVESTIGATOR AGREEMENT ...............................................................................................4 
LIST OF ABBREVIATIONS .....................................................................................................11 
PROTOCOL SYNOPSIS ............................................................................................................13 
1 KEY STUDY CONTACTS .................................................................................................22 
2 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ........................23 
2.1 Background Information ..................................................................................................23  
2.1.1  Keloids .......................................................................................................................23 
2.1.2  Human MicroRNA miR-29 .......................................................................................23 
2.1.3  Investigational Product: MRG-201 ............................................................................26  
2.2 Scientific Rationale ..........................................................................................................30 
2.3 Potential Risks and Benefits ............................................................................................31 
2.3.1  Known Potential Risks ...............................................................................................31 
2.3.2  Known Potential Bene fits ..........................................................................................32 
3 STUDY OBJECTIVES AND ENDPOINTS ......................................................................33 
3.1 Objectives ........................................................................................................................33 
3.1.1  Safety Objective .........................................................................................................33 
3.1.2  Pharmacodynamic Objective .....................................................................................33 
3.1.3  Other Objectives ........................................................................................................33 
3.2 Endpoints .........................................................................................................................33 
3.2.1  Safety Endpoints ........................................................................................................33 
3.2.2  Pharmacodynamic Endpoint ......................................................................................33 
3.2.3  Other Pharmacodynamic Endpoints ..........................................................................34 
3.2.4  Exploratory Endpoints ...............................................................................................34 
3.2.5  Pharmacokinetic Endpoints .......................................................................................35 
4 STUDY DESIGN ..................................................................................................................35 
4.1 Punch Biopsies .................................................................................................................36 
4.2 Treatments Administered .................................................................................................36 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 6 of 100 5 ENROLLMENT, DISCONTINUATION AND WITHDRAWAL OF STUDY 
PARTICIPANTS ..................................................................................................................37 
5.1 Inclusion Criteria .............................................................................................................37 
5.2 Exclusion Criteria ............................................................................................................38 
5.3 Participant Discontinuation or Withdrawal......................................................................40  
5.3.1  Reasons for Participant Discontinuation or Withdrawal............................................40  
5.3.2  Procedures for Participant Discontinuation or Withdrawal .......................................40 
6 STUDY PRODUCTS ...........................................................................................................41 
6.1 Study Product(s) Management .........................................................................................41 
6.1.1  Acquisition .................................................................................................................41 
6.1.2  Formulation, Appearance, Packaging, and Labeling .................................................41 
6.1.3  Storage and Stability ..................................................................................................41 
6.1.4  Accountability ............................................................................................................41 
6.2 Dosage, Preparation and Administration of Study Products............................................41 
6.2.1  Dose and Regimen .....................................................................................................41 
6.2.2  Method of Assignment to Treatment .........................................................................42 
6.2.3  Dose Preparation and Administration ........................................................................42 
6.2.4  Assessment of Treatment Adherence .........................................................................42 
6.2.5  Dose Modifications or Delays....................................................................................42 
6.3 Prior and Concomitant Medi cations ................................................................................43 
7 STUDY PROCEDURES .....................................................................................................43 
7.1 Clinical Assessments .......................................................................................................43 
7.1.1  Medical History .........................................................................................................43 
7.1.2  Vital Signs ..................................................................................................................43 
7.1.3  Physical Examination .................................................................................................44 
7.1.4  Prior and Concomitant Medications ..........................................................................44 
7.2 Safety Assessments ..........................................................................................................44 
7.2.1  Adverse Events ..........................................................................................................44 
7.2.2  Clinical Laboratory Assessments ...............................................................................44 
7.2.3  Electrocardiograms ....................................................................................................45 
7.3 Pharmacokinetic Sampling ..............................................................................................45 
7.4 Pharmacodynamic Assessments ......................................................................................45  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 7 of 100 7.4.1  Punch Biopsies ...........................................................................................................45 
7.4.2  Physician Assessment of Keloid Formation ..............................................................46 
7.4.3  Patient Reported Outcome .........................................................................................47 
7.4.4  Biopsy Wound Site Photography ...............................................................................47 
7.5 Pharmacodynamic Biomarkers ........................................................................................48  
7.6 Specimen Preparation, Handling, and Shipping ..............................................................48 
8 STUDY SCHEDULE ...........................................................................................................48 
8.1 Screening Period (Day -28 to Day 0) ............................................................... ................48  
8.2 First Cycle of Dosing with MRG-201 and Placebo with 6 Doses for Initial Treatment 
Cycle ................................................................................................................................49 
8.2.1  Day 1 (First Day of Study Treatment Administration) ..............................................49 
8.2.2  Day 2 ..........................................................................................................................50 
8.2.3  Days 3 and 5 ...............................................................................................................50 
8.2.4  Day 8 ..........................................................................................................................50 
8.2.5  Day 10 ........................................................................................................................51 
8.2.6  Day 12 ........................................................................................................................51 
8.2.7  Day 13 ........................................................................................................................52 
8.2.8  Day 19 (± 2 Days) ...................................................................................................... 52 
8.2.9  Day 29 (± 3 Days) ...................................................................................................... 53 
8.2.10  Days 57, 113, 141, 197, 225, 281, 309, 337 (± 7 Days) ............................................53 
8.2.11  Day 85 (± 7 Days) ......................................................................................................54 
8.2.12  Days 169 and 253 (± 7 Days).....................................................................................54 
8.3 Second Cycle of Dosing with MRG-201 and/or Placebo ................................................55 
8.3.1  Day 1 ..........................................................................................................................55 
8.3.2  Day 2 ..........................................................................................................................56 
8.3.3  Days 3 and 5 ...............................................................................................................56 
8.3.4  Day 8 ..........................................................................................................................56 
8.3.5  Day 10 ........................................................................................................................57 
8.3.6  Day 12 ........................................................................................................................57 
8.3.7  Day 19 (± 2 Days) ...................................................................................................... 57 
8.3.8  Day 29 (± 3 Days) ...................................................................................................... 57 
8.3.9  Subsequent Visits, Every 4 Weeks (± 7 Days) ..........................................................58 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 8 of 100 8.4 Dosing with MRG-201 and Placebo with 12 Doses for a Single Treatment Cycle .........58 
8.4.1  Day 1 (First Day of Study Treatment Administration) ..............................................58 
8.4.2  Day 2 ..........................................................................................................................59 
8.4.3  Days 3, 5, 10, 12, 17, 19 and 24 ................................................................................. 60 
8.4.4  Day 8 ..........................................................................................................................60 
8.4.5  Days 15 and 22 ...........................................................................................................60 
8.4.6  Day 26 ........................................................................................................................61 
8.4.7  Day 27 ........................................................................................................................61 
8.4.8  Day 29 (± 1 Day) .......................................................................................................62 
8.4.9  Day 36 (± 2 Days) ...................................................................................................... 62 
8.4.10  Days 57, 113, 141, 197, 225, 281, 309, 337 (± 7 Days) ............................................62 
8.4.11  Day 85 (± 7 Days) ......................................................................................................63 
8.4.12  Days 169 and 253 (± 7 Days).....................................................................................63 
8.5 End of Study Visit (Day 365 ± 7 Days) ...........................................................................64 
9 ASSESSMENT OF SAFETY ..............................................................................................65 
9.1 Specification of Safety Parameters ..................................................................................65 
9.2 Definition of Adverse Events ...........................................................................................65 
9.2.1  Adverse Event ............................................................................................................65 
9.2.2  Suspected Adverse Reaction ......................................................................................65 
9.2.3  Life-T hreatening AE or Life -Threatening Suspected Adverse Reaction...................65 
9.2.4  Serious AE or Serious Suspected Adverse Reaction .................................................65 
9.2.5  Unexpected AE or Unexpected Suspected Adverse Reaction ...................................66 
9.3 Adverse Event Classification ...........................................................................................66 
9.3.1  Relationship to Investigational Product .....................................................................66 
9.3.2  Severity ......................................................................................................................67 
9.4 Collection and Reporting of Adverse Events ...................................................................67 
9.4.1  Initial Reporting of Adverse Events ..........................................................................67 
9.4.2  Follow-up of Adverse Events ....................................................................................68 
9.5 Collection and Reporting of Serious Adverse Events ......................................................68 
9.5.1  Initial Serious Adverse Event Reports .......................................................................68 
9.5.2  Follow-up of Serious Adverse Events .......................................................................69 
9.6 Post-T rial Adverse Events ...............................................................................................70 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 9 of 100 9.7 Pregnancy Reporting and Follow-up ...............................................................................70 
9.8 Halting Rules ...................................................................................................................71 
9.9 Emergency Sponsor Contact ............................................................................................71 
10 TRIAL-S PECIFIC COMMITTEES ..................................................................................71 
11 STATISTICAL CONSIDERATIONS ...............................................................................71 
11.1  Statistical and Analytical Plans ........................................................................................71 
11.2  Study Hypotheses .............................................................................................................71 
11.3  Analysis Sets ....................................................................................................................71 
11.3.1  Full Analyses Set (FAS) ............................................................................................72 
11.3.2  Per Protocol Set (PPS) ...............................................................................................72 
11.3.3  PK Analysis Set (PKAS) ...........................................................................................72 
11.4  Statistical Methods ...........................................................................................................72 
11.4.1  General Approach ......................................................................................................72 
11.4.2  Analysis of Demographics and Other Baseline Characteristics.................................72 
11.4.3  Analysis of the Safety Endpoint: Safety and Tolerability..........................................72  
11.4.4  Analysis of Pharmacodynamic Endpoints: Keloid Formation ...................................73 
11.4.5  Analysis of Exploratory Endpoint: Pharmacokinetics ...............................................74 
11.4.6  Planned Interim Analyses ..........................................................................................75 
11.5  Sample Size Determination ..............................................................................................75 
11.6  Measures to Minimize Bias..............................................................................................75 
11.6.1  Randomization Procedures ........................................................................................75 
11.6.2  Evaluation of Success of Blinding .............................................................................75 
11.6.3  Breaking the Study Blind ...........................................................................................76 
12 DATA HANDLING AND RECORD KEEPING ..............................................................76 
12.1  Study Files and Patient Source Documents .....................................................................76 
12.2  Data Collection Methods .................................................................................................76 
12.3  Retention of Records ........................................................................................................77  
12.4  Protocol Deviations ..........................................................................................................78 
13 QUALITY CONTROL AND QUALITY ASSURANCE .................................................78 
14 ETHICS/PROTECTION OF HUMAN SUBJECTS ........................................................79 
14.1  Ethical Conduct of the Study ...........................................................................................79 
14.2  Institutional R eview Board Review .................................................................................79 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 10 of 100 14.3  Informed Consent Process ...............................................................................................80  
14.4  Confidentiality of Information .........................................................................................80 
14.5  Future Use of Stored Specimens ......................................................................................81  
15 PUBLICATION POLICY ...................................................................................................81 
16 REFERENCES .....................................................................................................................82 
17 LIST OF APPENDICES .....................................................................................................87  
LIST OF TABLES  
Table 1:  Key Study Contacts................................................................................................22  
LIST OF FIGURES  
Figure 1 : Sequence of Mature Human miR-29 Family MicroRNAs ....................................24 
Figure 2:  Pictorial Guide to Punch Biopsy Locations ...........................................................46 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidential   Page 11 of 100 LIST  OF ABBREVIATIONS  
AE A dverse event  
ALT  Alanine aminotransferase 
aPTT  Activated partial thromboplastin time  
AST  Aspartate aminot ransferase 
AUC 0-∞ Area under the curve extrapolated to infinity 
°C Degree(s) Celsius  
CFR  Code of Federal Regulations  
cGMP  Current Good Manufacturing Practice 
Cl Clearance  
CL/F Apparent clearance  
Cmax Maximum plasma  concentration 
CRA  Clinical Research Associate  
CRO  Contract Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events 
DLQI  Dermatology Life Quality Index  
DNA  Deoxyribonucleic acid  
ECG  E lectrocardiogram 
eCRF  Electronic case report form  
ECM  Extracellular matrix  
FDA  Food and Drug Administration 
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice 
HIV Human  immunodeficiency virus  
ICF Informed consent form 
ICH International Conference on Harmonization 
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
ITT Intent to Treat  
MedDRA  Medical Dictionary for Regulatory Activities  
miRNA  M icro ribonucleic acid  
mRNA M essenger ribonucleic ac id 
mVSS  Modified Vancouver Scar Scale  
NCI National Cancer Institute  
PI Principal Investigator  
PK Pharmacokinetic  
POSAS  Patient and Observer Scar Assessment Scale  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 12 of 100 PP Per Protocol 
PT Prothrombin time  
QTcF  QT interval corrected for heart rate using Fridericia’s formula  
RNA R ibonucleic acid  
SAE  S erious adverse event  
SAP Statistical analysis plan  
t1/2 H alf-life 
TGF -β Transforming growth factor beta  
TEAE Treatment -emergent  adverse event 
Th1 T helper 1  
Tmax T ime to maximum plasma concentration  
ULN  Upper limit of n ormal  
US United States  
USP United States Pharmacopeia  
UTR  Untranslated region 
Vz/F Volume of distribution of the terminal phase 
WHO- DD World Health Organization Drug Dictionary  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 13 of 100 PROTOCOL SYNOPSIS  
Sponsor:  miRagen Therapeutics, Inc. 
Protocol No.: MRG 201-30-201 
Title:  A Phase 2, Double-blind, Placebo- Controlled Study to Investigate 
the Efficacy, Safety and Tolerability of MRG -201 Following 
Intradermal Injection in Subjects with a History of Keloids 
Phase:  Phase 2  
Investigational Product 
and Comparators: Investigational Product: MRG -201 
The sponsor will provide MRG-201 (66 mg/mL active moiety) in sterile, single -use glass vials with a rubber closure and an  
aluminum flip -off overseal, each containing 0.3 mL of a clear to 
slightly yellow liquid formulation in isosmotic phosphate buffer, 
pH 7.4.  The study drug is stored at -20 ± 5°C.  MRG -201 will be 
administered by intradermal injections at the site of a sutured 
excisional wound, as instructed in study materials. 
The study sites will provide placebo comparator (0.9% sodium 
chloride injection, United States Pharmacopeia [ USP]) for 
intradermal injection at the site of a second sutured excisional 
wound. 
Population: Males/females, ≥ 18 years of age, with a history of a significant 
number of keloids (e.g., ≥ 10 individual keloids) or large keloids 
(e.g., ≥ 4 cm), where new keloids are likely to form with a punch biopsy 
Number of Participants 
Planned:  Up to 6 cohorts of 12-16 subjects each (a total of 96 subjects) may  
be enrolled in this study to evaluate different doses and regimens of MRG -201 given intradermally. 
Approximately 12 subjects are anticipated for enrollment in the 
first cohort.  Subjects who drop out for reasons other than safety or 
study treatment tolerability may be replaced with sponsor approval 
(up to 16 total including replacements ). 
Duration of 
Participation: Up to  393 days, including an up to 28-day screening period, a 
12-day to 26- day active treatment  period (first treatment cycle of
study dosing) , and a 52 -week  (± 7 days ) follow -up period af ter
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 14 of 100 Day 1 (i.e. the initiation of the first treatment cycle of study 
dosing).    
Anticipated Study 
Duration: 18 months 
Clinical Sites:  Approximately 4 centers in the United States  (US) 
Objectives:  
Safety Objective : 
Investigate the safety and tolerability of multiple intradermal administrations of MRG -201 in 
subjects with a history of keloids. 
Pharmacodynamic Objective : 
Investigate the activity of MRG -201 in prevention or reduction of keloid formation, in subjects 
with a history of keloid s. 
Other Objectiv es: 
•Evaluate additional pharmacodynamic endpoints of MRG-201 in subjects with a history
of keloids.
•Evaluate the effect of MRG -201 on skin- specific Patient Reported Outcomes.
•Characterize the pharmacokinetics of MRG -201 in subjects with a history of keloids.
Endpoints:  
Safety and Tolerability: 
•The safety and tolerability of MRG -201 will be assessed by determining the incidence
and severity of clinically significant adverse events (AEs), (including Grade 3 and 4 AEs,
treatment -related AEs, serious adverse events [ SAEs ], and AEs requiring discontinuation
of MRG -201), and physical examination findings, changes in vital signs,
electrocardiograms ( ECGs ), and laboratory parameters.
•AEs will be assessed according to the National Cancer Institute (NCI) Common
Termi nology Criteria for Adverse Events (CTCAE), version 5.0.
Pharmacodynamic: 
•Proportion of confirmed keloid formation across subjects for treated vs. untreated lesionsat 24 weeks .
•Proportion of subjects with improvement, which is defined as no confirmed keloid
formation in the treated lesion vs. confirmed keloid formation in the untreated lesions.
•Proportion of subjects forming confirmed keloids with MRG-201 treatment vs. placebo
treatment  at 12 weeks, 36 weeks, 52 weeks, and at the time of study withdrawal ( if
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Propr ietary and Confidentia l Page 15 of 100 subjects do not complete the study). 
Other Pharmacodynamic: 
•Proportion of subjects forming confirmed keloids regardless of treatment application .
•Time to keloid formation.
•Volume of keloid at 24 weeks , 52 weeks and at time  of triamcinolone injection (if
applicable) .
Exploratory: 
•Modified Vancouver Scar Scale (mVSS; Fearmonti et al 2010) s core at visits occurring  
every 4 weeks from Day 29 to Day 365 after excisional wound creation.
•Patient
 and Observer  Scar Assessment Scale (P OSAS) scores  at visits occurring every 4 
weeks from Day 29 to Day 
365 after excisional wound creation.
•Keloid volume and keloid s everity (per mVSS and POSAS) at visits occurring every 4 
weeks following a second cycle of dosing with MRG-201 or placebo in subjects  
exhibiting
 evidence that a keloid may be forming at one or both biopsy sites within 12 
weeks after initiation of the first cycle of study dosing. 
Pharm
acokinetic: 
•Plasma concentration of MRG -201 will be assessed at multiple time points on Day  1 an d
Day 1 2 (or Day 26 for cohorts dosing for 4 weeks), and at single time points on Day 2
and Day 13 (or Day 27 for cohorts dosing for 4 weeks). Voided urine samples for PK
analyses will also be collected on Day 1  and 12 (or day 26 for cohorts dosing for 4
weeks) predose an d 3 hours postdose, and Day 2  and Day 13 (or day 2 7 for cohorts
dosing for 4 weeks).
Study Design: 
This is a double-blind, placebo-controlled, multi- center, exploratory safety and efficacy study in 
subjects with a high frequency of keloid formation  (i.e., history of ≥ 10 keloids  or history of large 
keloids, ≥ 4 cm ), with MRG -201 and  placebo  administered by intradermal injection around the 
site of two separat e punch biopsies. 
A minimum of 12 subjects are anticipated for enrollment in the first cohort of the study to attain 
at least 10 subjects who complete study participation  through 24 weeks after excisional wound 
creation .  Subjects who drop out for reasons other than safety or study treatment tolerability may 
be replaced with sponsor approval (up to 16 total including replacements).  The sponsor may 
enroll up to 5 additional cohorts of 12 to 16 su bjects each (up to 80 total additional subjects) to 
assess lower  doses and/or additional regimens.   
Subjects will receive a maximum of twelve doses of 5.3  mg MRG -201 throughout the duration 
of the study.  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 16 of 100 Methodology:  
Subjects in the initial cohort will u ndergo a screening period lasting up to 28  days , followed by a 
double-blind, 12- day active treatment period (first cycle of study dosing) conducted in the 
outpatient setting , a possible second 12-day cycle of study dosing, and a follow-up period of up 
to 52 weeks (±  7 days) after  initiation of the first cycle of study dosing . 
On Day 1  of the study , subjects will be seen at the clinic in the morning to confirm study 
eligibility and for their baseline assessments, punch biopsy procedures, baseline photography of 
the biopsy sites, and administration of study treatments.  Subjects will undergo two 6-mm punch 
biopsies bilaterally in the upper back/shoulder region in areas that can be covered with clothing and are likely to form  keloids.  The locations for the biopsies must be at least 10  cm from each 
other and far enough away from existing keloids that new keloid formation may  be assessed.  
The punch biopsy excisional wound sites will be closed with sutures.  One wound site will be 
treated with MRG -201 and the other wound site will be treated with placebo .  The treatment for 
each wound site will be randomized (left versus right) and blinded but consistent throughout 
dosing.  MRG -201 and placebo will each be administered as four 20-µL injections around one 
wound sit e, with s ubjects receiv ing approximately 5.3 mg of the MRG -201 active moiety on 
each dosing day (approximately 1.3 mg per 20- µL injection).   After all Day 1 assessments and 
procedures are complete, subjects will be discharged to home. 
Subjects will return to the clinic on Days 3, 5, 8, 10, and 12 to receive repeat injections with the 
same blinded study treatment  that was administered at  each wound site  on Day 1.  Subjects will 
return to the clinic on Day 19 for additional assessments and safety monitoring, and t he Principal 
Investigator ( PI) will determine  whether any tolerability concerns are present and warrant 
consultation  and safety data review with the sponsor ’s Medical Monitor.  If at any point 
clinically significant safety or tolerability issues are o bserved by the investigator and are thought 
to be possibly related or related to MRG -201, the subject will not receive further administration 
of MRG -201 pending follow-up with the Medical Monitor.  In this event, the investigator must 
notify the sponsor’s Medical Monitor by email or phone within 24 hours, and a meeting with the 
sponsor Medical Monitor may  be convened.  
On Day 8, Day 12, Day 19, Day 29 (4 weeks ± 3 days after completion of the punch biopsies) 
and then every 4 weeks for 1 year (Days 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365, each ± 7 days), excisional wound sites will be assessed for keloid formation, photographic 
evaluations, and other study assessments. 
For subjects receiving 6 doses of MRG- 201 in the initial treatment cycle, if there is evidence that 
a keloid may be forming (defined as meeting a score of 1 or 2 on the mVSS and having an appearance consistent with an area likely to form a keloid according to investigator judgement) 
within 12 weeks after initiation of the first c ycle of study dosing, and following the initial 29- day 
treatment and assessment period, subjects will undergo a second cycle of study dosing in one or 
both biopsy site s (depending on keloid formation) . Subjects  will be treated with MRG -201 or 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 17 of 100 placebo accor ding to  the original treatment assignments (blinding will be maintained during the 
second treatment regimen) .  The treatment regimen for the second cycle of study dosing will be 
the same as  for the first cycle , i.e., an initial dose followed by additional doses 2, 4, 7, 9, and 
11 days after the initial dose, with follow -up visits at Day s 19 and 29 after the re-start of dosing.  
After these follow -up visits, the subject will resume the original study schedule, with visits 
occurring every 28 days until the Day 365 visit.  If the wound site scar(s) progress to a n mVSS 
score of 3  to 5 (with a score of at least 1 in the height sub-domain) after the 12 -week observation 
period and/or to an mVSS score of ≥ 6 (with a score of at least 1 in the height sub-domain) at any 
time, the scar(s) will be considered confirmed keloid(s).  At the time of keloid confirmation , the 
investigator, in consultation with the subject, may elect to attempt local treatment of the keloid 
with triamcinolone as a standard of care therapy  after consultation with the sponsor. 
Additional cohorts may be enrolled to test lower doses or an extended dosing schedule.  Study 
procedures for the extended dosing cohorts will be identical to the c ohort described above, with 
the following exceptions: 1) subjects in these cohorts may  receive a total of 12  intradermal doses 
of MRG -201 and placebo on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26; 2) s ubjects  will 
not undergo a second cycle of tre atment  if the 4 -week dosing schedule is used; and 3) 
pharmacokinetic assessments will be performed on study Day 1, 2, 26 and 27 if the 4 -week  
dosing schedule is followed. 
Pharmacodynamic Endpoint Assessment: 
Subjects will be evaluated for the incidence, timing and physical characteristics of keloid 
formation. The punch biopsy wound site s will be evaluated for keloid formation, photographic 
assessment, and clinical response during the active treatment and follow -up periods of the study, 
which will last 52 w eeks (± 7 days ) after initiation of the first cycle of study dosing .  Scars that 
form at one or both punch biopsies wound sites will be considered unconfirmed keloid(s) if they 
exhibit a score of 3 to 5 on the mVSS, with a score of at least 1 in the height sub-domain.  
Unconfirmed keloid(s) with a score of 3 to 5 on the mVSS will be re -evaluated at the subsequent 
monthly visits for up to 12 weeks.  Kel oid(s) that persist after this 12 -week observation period 
and/or progress to an mVSS score of ≥ 6 ( with a score of at least 1 in the height sub -domain) at 
any time will be considered confirmed keloid(s).  At the time of keloid confirmation, the 
investigator, in consultation with the subject, may elect to attempt local treatment of the keloid 
with triamcinolone as a standard of care therapy  after consultation with the sponsor. 
Biopsy samples will be saved for future protein and/or nucleic acid analysis to as sess MRG -201 
effects in subjects who form keloids. 
Safety and PK Assessments:  
Subjects in all cohorts will be continuously monitored for safety through evaluations of AEs, 
vital signs, physical examination findings, clinical laboratory measurements, and EC G 
monitoring. 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 18 of 100 Samples will be collected for plasma pharmacokinetic(s) on Days 1, 2, 12, and 13 ( or study 
Days 1, 2, 26, and 27 for subjects receiving an initial 26- day treatment cycle ). 
Main Criteria for Inclusion:  
1.Must  provide written informed consent (signed and dated), and any authorizations
required by law, and be able to comply with all study requirements.
2.Males or females, ≥ 18 years of age at the time of informed consent.
3.Females must have a negative serum pregnancy test at screening and a negative urine
pregnancy test on their first dosing day.
4.Females must not be or planning to be pregnant or lactating during the study. Females
must be post-menopausal (confirmed by follicle- stimulating hormone [FSH] test for
subjects whose last  menstrual cycle was within the last 2 years  before screening ),
abstinent, in a monogamous same sex relationship, surgically sterile or, if of child bearing
potential, must use two acceptable methods of contraception with at least one being a
barrier method throughout their study participation and for at least 6 months followingthe last dose of study treatment.  Acceptable methods of contraception include oral,
injectable or implantable hormonal contraception, intrauterine device,  or medically -
confirmed vasectomized partner.
5.Males must be surgically sterile, abstinent, or if engaged in sexual relations with a femaleof child-bearing potential, mu st be using two acceptable methods of contraception with at
least one being a barrier method for at least 6 months following the last dose of study
treatment .  Contraception for male subjects could include a condom and a highly
effective second method during and for at least 6 months after the last dose of studytreatment .
6. History of a high frequency of keloid formation (history of ≥ 10 keloids), or a history of
large keloids (≥ 4 cm) and Investigator feels that the subject is likely to form keloids in
the upper back/shoulder area after punch biopsy.
7. Must have bilateral 2 cm × 2 cm areas, where skin punch biopsy may be performed in the
upper back/shoulder region and can be covered by clothing, that are free of keloids, acne,striae or other skin pathologies or complications (e.g., tattoos, excessive hair) that mayobstruct the ability to evaluate the biopsy sites.
8. S ubject is currently clinically stable and is likely to remain clinically stable for a
minimum of 14 months from s creening .
9.Subject is not anticipated to require systemic corticosteroids during participation in the
study.
10.Must be able to communicate effectively with study personnel.
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 19 of 100 Main Criteria for Exclusion:  
1. Recent history of alcoholism (within the past 1 year). 
2. History of drug a buse or use of il licit drugs (such as cocaine, methamphetamines, or 
heroin) within 1 year prior to s creening .  Subjects must also agree to refrain from illegal 
drug use during the study. 
3. Systemic use of steroids within 4 weeks of Day 1, or local use of steroids within 1 we ek 
of Day 1 . 
4. An active or uncontrolled infection at screening or Day 1 . 
5. Positive at the time of screening for human immunodeficiency virus ( HIV), Hepatitis B 
(surface antigen), or Hepatitis C . 
6. Liver dysfunction, as defined by alanine aminotransferase (ALT) , aspartate  
amino transfer ase (AST), bilirubin, or alkaline phosphatase > 1.5 × upper limit of normal 
(ULN ) at screening or Day 1 . 
7. Renal dysfunction defined as serum creatinine > 2 mg/dL at screening or Day 1 . 
8. Clinically significant anemia, neutropenia , or thrombocytopenia at screening or Day 1. 
9. History of bleeding diathesis or coagulopathy. 
10. Genetic disorders that predispose to keloids. These include, among others, Ehlers-Danlos 
syndrome, Ullrich congenital muscular dystrophy, and Rubenstein-Taybi syndrome. 
11. Prior malignancies within the past 3 years (allowing squamous cell and basal cell 
carcinomas with free margins at excision, or other malignancies considered cured by 
surgical resection) . 
12. Presence on ECG of QT interval corrected for heart rate using Frideri cia’s formula 
(QTcF) > 450 msec or > 480 msec if concomitant bundle branch block, at screening or 
Day 1 . 
13. Use of an investigational small molecule drug during the 30 days prior to screening or 
use of an investigational oligonucleotide or biologic drug during the prior 90 days. 
14. History of allergy or severe adverse reaction to an oligonucleotide. 
15. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator. 
16. Clinically significant abnormalities in medical history, physical examination, or 
laboratory values  that,  in the opinion of the Investigator, would make the subject 
unsuitable for inclusion in the study.  
Statistical Methods:  Safety Endpoints:  
• Descriptive analysi s of safety endpoints will be listed per 
patient for each assessment,  and descriptive statistics may 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 20 of 100 be tabulated for select criteria.  
Pharmacodynamic endpoints: 
•Proportion of keloid formation across subjects for treated
vs. untreated lesions.
Other pharma codynamic endpoints: 
•Proportion of subjects forming keloids.
•Intra -patient and aggregated time from initial treatment on
Day 1 to unconfirmed and confirmed keloid formationsubjects in treated vs. untreated lesions.
•Intra -patient and aggregated keloid volum e between treated
and untreated lesions at 6 months, 12 months, and at thetime of triamcinolone intervention (if applicable) forsubjects in treated vs. untreated lesions.
Exploratory endpoints: 
•Difference in mVSS and POSAS scores within subjectsand acro ss subjects for treated vs. untreated lesions.
Pharmacokinetic Endpoints: 
•PK parameters (C
max, Tmax, Terminal half -life (t1/2),
volume of distribution at steady state (Vss), clearance (Cl),
AUC 0-∞) will be derived from plasma concentrations of
MRG -106 using the actual sampling times. Concentration
data and all PK parameters will be listed per patient andsummarized descriptively per dose.
Details of any statistical testing and data  summaries  will be 
described in the Statistical Analysis Plan, which will be finalized prior to the database lock and the clinical study report. 
Sample Size Justification:  Approximately 12 subjects are anticipated for  enroll ment  in the 
first cohort  to attain approximately 10 subjects who complet e 
study participation through at lea st 24 week s.  A sample size of 
10 subjects on active treatment is  considered  to be adequate for 
analysis of safety in this early Phase 2 study.   Additional subjects 
may be enrolled, up to a total of 16, if fewer than 10 subjects 
complete study participatio n through 24 weeks for reasons other 
than the safety or tolerability of study treatment , or if dosing is not 
completed per protocol for an individual subject for reasons other than the safety or tolerability of study treatment . 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 21 of 100 The sponsor may enroll  up to 5 additional cohorts of 12 to 
16 subjects each (up to 80 total additional subjects) to assess lower 
doses or alternative  regimens.  As with the first cohort, additional 
subjects may be enrolled in the additional cohorts, up to a total of 
16 each, if fewer  than 10 subjects in a given cohort complete the 
study through 24 weeks for reasons other than the safety or 
tolerability of study treatment, or if dosing is not completed per 
protocol for an individual subject for reasons other than the safety 
or tolerabi lity of study treatment . 
Planned Interim 
Analysis: Aggregated blinded interim analyses will be completed when at least 50% of the study subjects reach 12 weeks, 24 weeks, 
36 weeks and 52 weeks after study Day 1.  
Trial -specific 
Committees:  No independent safety or data review committee will be used.  The 
Sponsor and investigator will oversee subject  safety based on 
results of the safety and local tolerability assessments.  
Protocol Version and 
Date:  Version 1.0, Final , 16 March 2018 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Proprie tary and Confidentia l Page 22 of 100 1 KEY STUDY CONTACTS  
A contact information list for the Sponsor, Contract Research Organization ( CRO ), and selected 
service providers will be provided to each site.  General advice on protocol procedures should be 
obtained through the monitor assigned to each  trial site.  Inf ormation on service providers is 
given in the study reference manual provided to each  site. 
The following table lists contact information for investigator reports of serious adverse events 
(SAEs) and pregnancies occurring in study participants, as well as responsible personnel 
representing  the Sponsor and the CRO. 
Table 1: Key Study Contacts 
Role  Name and 
Affiliation  Phone  Email 
Sponsor Study 
Lead   
 
miRagen 
Therapeutics, Inc.   
  
Serious Adverse 
Event and Pregnancy 
Reporting    
 
 
  
Responsible Medical Officer 
or Medical Lead   
 
miRagen 
Therapeutics, Inc.   
  

miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 23 of 100 2 BACKGROUND INFORMATION AND SCIENTIFIC RA TIONALE  
2.1 Background Information  
2.1.1 Keloid s 
Keloids are abnormal wound responses characterized by local  fibroblast proliferation and 
overproduction of collagen in predisposed individuals, and represent an excessive connective 
tissue response to dermal trauma, inflammation , surgery, or burns ( English et al 1999 ; 
Nemeth  1993; Teofoli et al. 1999 ).  Fibroblasts and myofibroblasts are believed to be responsible 
for the deposition of dense ext racellular matrix consisting of collagen and glycosaminoglycans. 
Attempts to clinically differentiate keloids from hypertrophic scars have proved to be difficult in 
the early phases of formation . Both scar types demonstrate overproduction of multiple fibroblast 
proteins, including fibronectin, suggesting either pathological persistence of wound healing 
signals or a failure of the appropriate downregulation of wound- healing cells (Sephel  et 
al. 2001 ). However, keloids seem to be a more sustained and aggressive fibrotic disorder than 
hypertrophic scars ( Brown et al 2009 ).  Evidence to date suggests a more prolonged 
inflammatory period,  with immune cell infiltrate present in the scar tissue of keloids, whic h may 
contribute to increased fibroblast activity and more sustained extracellular matrix ( ECM ) 
deposition ( Brown et al 2009 ). As a result, the keloid scar  tissue by definition extends beyond the 
borders of the original wound into the normal skin and is frequently pruritic and painful.  Unlike 
hypertrophic scars, keloids do not usually regress spontaneously and tend to recur after excision.  
2.1.2 Human MicroRNA miR -29  
2.1.2.1 Role of miR-29 in Tissue Homeostasis 
miRNAs are small, non -coding RNAs of approximately 22- nucleotides in length that act as 
negative regulators of gene expression.  miRNAs interact through homologous base pairing with 
the 3’ untranslated regions (UTR) of specific mRNA targets to inhibit translation or promote mRNA degradation ( Bartel 2009) .  The human genome is predicted to encode more than 2000 
miRNAs, which as a class are estimated to regulate as many as 60% of mRNA transcripts (Friedman et al. 2009) .  To date, the functions of only a handful of miRNAs have been 
characterized, but their powerful effects on cellular phenotypes, impact on a substantial fraction of the genome, and evolutionary conservation point to miRNAs as key regulators of physiological processes.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 24 of 100 The miR -29 family contains four miR-29 genes, located in two bi- cistronic clusters in the 
genome.  miR -29a and miR-29b- 1 are one cluster and miR -29c and miR-29b-2 make up the 
other.  miR -29b-1 and miR-29b- 2 have identical mature miRNA sequences.  Collectiv ely, these 
four genes result in three mature miRNAs, miR -29a, miR-29b, and miR-29c ( Figure 1), which 
are 100% conserved from human to non-human primate to laboratory animals, nearly 100% 
conserved across other mam mals, and have a high degree of homology to other vertebrates such 
as frog and chicken (http://people.csail.mit.edu/akiezun/microRNAviewer/all_mir -29.html).  The 
miR-29 family members share a common seed region sequence and are predicted to target 
largely overlapping sets of genes.  The miR -29 family is expressed in fibroblasts and other cell 
types in humans ( Liang et al. 2007)  and mice (Thomson et al. 2004; van Rooij et al. 2008).  
Figure 1 : Sequence of Mature Human miR -29 Family MicroRNAs 
 
miR-29a 5’-U AGCACCAUCUGAAAUCGGUUA -3’ 
miR-29b 5’-U AGCACCAUUUGAAAUCAGUGUU -3’ 
miR-29c 5’- U AGCACCAUUUGAAAUCGGUUA -3’ 
 
The seed region (nucleotides 2 -8) is under lined  in each sequence . 
Predicted targets for miR -29 suggest important roles for this microRNA in connective tissue 
maintenance and repair , hematological function and cancer, and in the cardiovascular and 
nervous systems ( Liston  et al. 2012) .  The regulation of extracellular matrix by the miR -29 
family is a dramatic example of a single microRNA family regulating a large set of functionally related genes.  miR -29 family members target key proteins involved in the physiological or 
pathological formation of extracellular matrix including collagen genes, lamininγ1, fibrillin 1, elastin, matrix metalloproteinase 2, and integrin β1 (Li et al. 2009; Liu et al. 2010; 
Sengupta et al. 2008; van Rooij et al. 2008).  The ECM is a highly dynamic structure, 
undergoing continuous remodeling, including the deposition, degradation, and modification of its components.  The capacity of miR -29 to modulate many distinct components of the extracellular 
matrix indicates a role for this microRNA in ECM homeostasis in a variety of tissue contexts, including skin ( Cheng et al. 2013; Maurer et al. 2010
; Zhang et al. 2016),  bone ( Li et al. 2009), 
eye (Villarreal  et al. 2011) , heart (Boon et al. 2011; van Rooij et al. 2008) , vasculature and 
circulation (Fort et al. 2010; Ott et al. 2011), liver (Roderburg et al. 2011) , lung 
(Montgomery et  al. 2014 ), and kidney ( Liu et al. 2010; Qin et al. 2011).  Production of 
extracellular matrix is also important for the integrity and structural support of the aortic wall, and dysregulation of miR-29 has been linked to aortic aneurysm disease (Boon et al. 2011; 
Maegdefessel et al. 2012 ). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 25 of 100 The miR -29 family has multiple functions in the hematopoietic system, including both adaptive 
and innate immunity.  miR -29 maintains hematopoietic stem cell renewal through regulation of 
DNMT3a (Hu et al. 2015 ).  miR -29 supports a critical function in T cell production in a T 
cell-extrinsic  manner, by preventing inappropriate thymic atrophy (Papadopoulou et al. 2012).  
The miR -29 family is highly expressed in adaptive immune cells and has a critical T 
cell-intrinsic function in determining polarization into different effector T cell fates.  miR -29a 
and b were identified as critical suppressors of the T helper 1 ( Th1) cell fate, setting the threshold 
for Th1/Th2 balance and being able to correct the Th1 bias of DGCR8-/- miR -deficient CD4 T 
cells (Steiner et al. 2011 ).  In agreement with these findings, miR-29 inhibition in mice removed 
this counterbalancing force and led to an increase in the number of Th1 cells and interferon -γ 
production ( Ma et al. 2011 ).  miR -29 is induced in myeloid and lymphoid cells in response to 
immune signals, and it down- regulates multiple immune modulators including interleukins 
(Brain  et al. 2013), interferon -γ (Smith et al. 2012) , and the immunomodulatory glycoprotein 
B7-H3 (Xu et al. 2009).   
The importance of miR -29 function in maintenance of tissue homeostasis is demonstrated by the 
fact that loss of miR -29 function is associated with fibrosis and cancer.  Decreased expression of 
miR-29 has been reported for a majority of cancers (Jiang et al. 2014)  and diverse cancer types 
including leukemia (Calin et al. 2005; Garzon et al. 2008; Garzon et al. 2009; 
Pekarsky  et al. 2000) , melanoma ( Nguyen et al. 2011) , and cancers of the live r 
(Xiong et al. 2010) , colon ( Cummins et al. 2006) , and lung (Yanaihara et al. 2006 ), and 
down- regulation of miR -29 has been associated with more aggressive forms of cancer or relapse 
(Calin et al. 2005; Pekarsky  et al. 2000; Zhao et al. 2010).   As a tumor suppressor, miR-29 
constrains cancer progression by promoting apoptosis, increasing chemosensitivity, reducing 
proliferation, and suppressing DNA methylation of tumor- suppressor genes.  However, 
up-regulation of miR -29 has been reported in a minority of cancers and might promote 
metastasis of breast and colon cancer by mediating epithelial -mesenchymal transition 
(Jiang  et al. 2014).  
2.1.2.2 Role of miR -29 in Fibrotic Disease  
Of all the studied miRNAs in fibrotic disease, the miR -29 family is the most consistently 
dysregulated during disease progression.  All three family members are reduced in different 
types of tissue fibrosis, and therapeutic benefit of increasing miR -29 levels has been shown for 
heart (van Rooij et al. 2008) , kidney ( Qin et al. 2011; Wang et al. 2012; Xiao et al. 2012 ), liver 
(Roderburg et al. 2011; Sekiya et al. 2011; Zhang et al. 2012) , lung (Cushing et al. 2015; 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 26 of 100 Xiao  et al. 2012) , and systemic sclerosis (Maurer et al. 2010 ).  The microRNAs in the miR -29 
family are understood to play a role in the regulation of key processes that co ntribute to fibrosis, 
including the initiation and maintenance of fibrosis through transforming growth factor beta 
(TGF-β) signaling (Li et al. 20 09; Peng et al. 2012 )  and ECM deposition (Cheng et al. 2013 ; 
Kawashita et al. 2011 ; Peng  et al. 2012; Zhu et al. 2012 ).  Furthermore, both fibrotic ECM and 
TGF -β can down- regulate miR -29 expression, leading to a feed-forward loop for increased 
TGF -β expression and uncontrolled ECM production ( Parker et al. 2014; Peng  et al. 2012 ). 
miR-29 expression is reduced in multiple fibrotic indications ( Liu et al. 2010; Maurer et al. 2010 ; 
Pandit et a l. 2011; Qin et al. 2011; Roderburg et al. 2011; Sekiya et al. 2011; van Rooij et al. 
2008 ), and miR-29 expression level has been inversely correlated with the severity of fibrosis 
(Cushing et al. 2015 ).  Expression of miR-29b in a mouse model of lung fibrosis resulted in 
protection against, and reversal of, fibrosis ( Montgomery et al. 2014 ), demonstrating the 
therapeutic potential of mimicking miR -29 function. 
In addition to organ fibrosis, several  studies have shown a role for miR-29 in dermal fibrosis, 
systemic sclerosis  and keloid fibrogenesis.  Fibroblasts and skin sections obtained from patients 
with systemic sclerosis , and primary fibroblasts derived from patients with keloids, were lower 
in miR-29 levels compared to healthy controls (Maurer et al. 2010 ; Zhang et al. 2016). 
Bleomycin -treated skin show ed a significant reduction in miR -29 as well, suggesting miR -29 
down-regulation is a common feature of cutaneous fibrosis regardless of etiology 
(Maurer  et al. 2010 ).  When overexpressed in systemic sclerosis fibroblasts or keloid fibroblasts, 
miR-29 was able to robustly reduce the expression of type I and III collagens, at both the RNA 
and protein level.  Conversely, inhibition of miR-29 in normal fibroblasts resulted in an increase 
in these collagens.  Additionally, miR-29 overexpression in dermal fibroblasts decreased 
secreted TIMP -1 and increased collagen gel degradation.  Collectively, these studies point to 
miR-29 mimicry as having therapeutic potential in the prevention or treatment of organ fibrosis, 
including in the dermis. 
2.1.3 Investigational Product: MRG-201 
miRagen has designed a mimic of miR -29b, MRG-201, with the objective of correcting the 
deficiency of miRNA -29 in fibrotic disease states.  The structure of MRG -201 was selected by 
screening a panel of synthetic oligonucl eotides for activity as measured by miR -29b target gene 
repression in cultured cells in vitro  and in animals in vivo .  The safety, tolerability, 
pharmacokinetics (PK) and pharmacodynamics (PD) of MRG -201 have been evaluated in 
nonclinical studies, as well as in a Phase 1 clinical trial in healthy human volunteers.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 27 of 100 Of note, all  the completed nonclinical and clinical studies of MRG-201, summarized below, 
defined the selected dose of the investigational product based on the mass of the sodium salt 
form of the  active pharmaceutical ingredient.  In this Phase 2 protocol, the dose of MRG-201 is 
defined based on the mass of the active moiety (protonated or free acid form) of MRG -201.  A 
conversion factor of 0.94 must be applied to convert a dose based on the mass of the sodium salt 
to the same dose based on the mass of the active moiety.   
2.1.3.1 Nonclinical Background 
miRagen has conducted in vitro  and in vivo  studies to investigate the pharmacology, PK , and 
toxicology of MRG -201.  Complete details of nonclinical studies c onducted to date are provided 
in the MRG -201 Investigator’s Brochure. 
The pharmacology of MRG-201 has been assessed in single and multiple dose studies in intact skin and acute skin incisions in mouse and rat, in hypertrophic scars in rabbits, and in human skin fibroblasts in culture.  Evidence of reciprocal regulation of mRNA levels by a miR-29b mimic and a miR -29 antagonist was used to identify direct and indirect targets of miR-29b in 
mouse skin.  A similar pattern of gene expression changes was observed in response to MRG -201 treatment in incised skin of rats and hypertrophic scars in rabbits and in cultured 
human skin fibroblasts, consistent with the conservation of the miR- 29b sequence across species 
and the ubiquitous role of miR-29 in regulation of e xtracellular matrix production.  These data 
were used to select a panel of 24 mRNAs to be monitored as PD biomarkers of MRG-201 
activity in human clinical trials.  In these pharmacology studies, distribution of MRG-201 along 
the margin of an incision using multiple, small volume injections was found to reduce the local inflammation associated with intradermal administration of MRG -201 while preserving its 
effects on gene expression.  The microinjection strategy was therefore used for dose administration in Good Laboratory Practice ( GLP ) toxicology studies performed in rats and 
rabbits and was used for administration of MRG-201 to Phase 1 clinical study participants. 
The pharmacokinetics and biodistribution of MRG -201 have been  studied in mice , rats and 
rabbi ts following intradermal or intravenous injection, and in monkeys following subcutaneous 
injection. The non- clinical studies suggest MRG -201 has low bioavailability (≤ 20%) when 
administered as a local intradermal dose. In rats and rabbits  dosed at 0.8, 2.5 or 7 mg MRG-201 
using 8 intradermal microinjections around a 1.5 cm incision, MRG-201 plasma concen trations 
peaked  between 15 minutes and 2 hours and cleared quickly , with half -lives typically under 
5 hours.  Though there was some evidence of increased C
max (rat and rabbit) and accumulation 
(rat only) between Days 1 and 26 of dosing, the levels of MRG-201 at 48 hours post-dosing were 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 28 of 100 generally below the limit of quantitation. Data from the Phase 1 clinical study suggest  a similarly 
low level of systemic exposure to MRG -201 in healthy volunteers administered repeat 
intradermal injections  at doses ranging from 4 to 14 mg per dose. In addition, dose range-finding 
embryo -fetal development studies in rats and rabbits demonstrat ed very low  tissue  uptake and/or 
rapid clearance from tissues, even after high, sustained plasma exposure of MRG-201. 
MRG -201 is rapidl y metabolized following intradermal or subcutaneous administration in rats, 
rabbits and monkeys into a number of smaller species that are likely to correspond to nucleotide 
truncations from the 5′ or 3′ end of the antisense strand of the oligonucleotide duplex.  The largest of these metabolites are biologically active in vitro  and in vivo  and may contribute to the 
pharmacological activity of the drug in humans.  Structural characte rization of the metabolites is 
ongoing, and further work is needed to determine if the same metabolites are formed in humans.  
The safety of MRG -201 has been assessed in repeat intradermal dose studies (0.8-7 mg) in rats 
and rabbits and with single subcutaneous escalating doses (2 and 20 mg/kg) in cynomolgus monkeys. The primary safety concern observed in the rabbit studies was a mix ed cell 
inflammatory reaction at the injection site at a dose of ≥ 2.5 mg, although neither erythema nor edema were reported.  In the thymus, there was mild to moderate lymphoid depletion 
characterized by a decreased number of lymphocytes in the cortex accompanied by diminished cortical-medullary demarcation  in male and female rabbits at doses ≥ 0.8 mg.  This change was 
interpreted to be a minor stress reaction to inflammation at the dose site.   In the rat, erythema and 
edema were reported  at the injection site but the histological findings included only a minor 
monocyte infiltration at the highest dose tested (7 mg).  Safety pharmacology s tudies using 
cynomolgus monkeys dosed subcutaneously with 2 or 20 mg/kg MRG-201 demonstrated no 
effects on any of the measured respiratory or cardiovascular parameters  with the exception of 
transient, non-significant changes in blood pressure and heart rate at 60 minutes, but not at 45 minutes or 2 hours after a dose of 20 mg/kg. MRG -201 administration produced no clinical 
signs or injection site reactions  and there were no effects on electrocardiogram waveform, or 
morphology at any dose level tested.   
In the embryo/fetal development dose range-finding toxicity studies in rats and rabbits, there was 
no relevant MRG- 201 exposure in the fetal homogenates tested , and no external fetal 
malformations or variations at any dose level in either species. In addition, MRG-201 did not 
show mutagenic activity in the bacterial mutagenicity assay (Ames test), nor any clastogenic or 
aneugenic effect in the micronucleus assay in human lymphocytes. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 29 of 100 The starting dose selected for this Phase 2a study is 5.3 mg (active moiety) MRG -201 (0.09 
mg/kg based on a 60 kg person) administered initially as 6 intradermal doses over 2 weeks . This 
dose level  is essentially equivalent to the calculated no -observed-adverse- effect level (NOAEL) 
identified in rabbits [0.8 mg or 0.26 mg/kg for 3.1 kg rabbit, scaled to the human equivalent dose 
based on body surface area: 0.26 mg/kg × 0.32 ( body surface area scalin g factor ) = 0.08 mg/kg , 
or 5 mg for 60  kg person]. Therefore, t he results of nonclinical and clinical studies  discussed 
below indicate that this dose and dosing regimen should be safe and well -tolerated . 
2.1.3.2 Clinical Background 
MRG -201 was evaluated in a Phase 1, first -in-man, double-blind, placebo-controlled, 
single -center, single and multiple dose- escalation study  (protocol MRG201-30-001) to 
investigate the safety  and tolerability of intradermal injections  of MRG -201 in intact and sutured 
skin of normal healthy volunteers.  The starting dose of MRG -201 (administered to the first 
sentinel subject  and cohort) was 0.5 mg (sodium salt form) , which was calculated from the 
NOAEL  identifie d in rabbits, and then adjusted by a 10-fold safety margin to 0.5 mg/dose. 
Fifty-four male subjects were enrolled, 47 of whom received MRG-201, across 4 study parts: 
Part A (untreated sutured incisions , N = 6 ), Part B (single -ascending dose of MRG-201 and 
placebo injected into intact skin , N = 1 9), Part C (single -ascending dose of MR G-201 and 
placebo injected into sutured incisions , N = 9 ), and Part D (multiple -ascending dose of 
MRG -201 and placebo injected into sutured incisions, N = 20).  Subjects were monitored for 
safety (including local skin reactions), drug biodistribution, PD , and histologic and photographic 
assessments.  
Overall, 32 subjects (59%) experienced at least 1 AE, including 2 subjects (33%) in Part A, 
11 subjects (58%) in Part B, 4 subjects (44%) in Part C, and 15 subjects (75%) in Part  D.  
Approximately one- half of su bjects ( 28 subjects [52%] ) experienced Grade 1 AEs, and 7 subjects 
(13%) experienced Grade 2 AEs.  Two subjects (4%) experienced AEs of Grade 4 blood creatine 
phosphokinase increased that were considered  to be most likely attributable to increased  physical  
activity and changes in diet .  These laboratory abnormalities were not associated with symptoms , 
were considered to be not related to  MRG -201 and returned  to baseline values without sequelae. 
The most common individual treatment -emergent AEs ( TEAEs ) follo wing study injection s (i.e., 
AEs reported in Parts B, C, and D; N = 48) were injection site edema and  nasopharyngitis (each 
8 subjects [17% ]) and injection site erythema  and headache  (each 6 subjects [13%]).  The 
majority of MRG -201- related TEAEs were inje ction site erythema or edema, consistent with the 
intradermal route of administration of the product.  The incidence of TEAEs following 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 30 of 100 single -dose administration of MRG-201 (Part B and Part C) and multiple-dose administration of 
MRG -201 (Part D) was similar and relatively low across MRG -201 dose levels, with no direct 
relationship observed between dose level and incidence of TEAEs.  
No deaths or SAEs were reported.  One subject enrolled in Part D withdrew consent from the 
study after experiencing 2 concurrent TEAEs: Grade 1 injection site edema and Grade 1 injection 
site pruritus.  
The Phase 1 study results indicate that MRG -201 was safe and well tolerated at all tested 
concentrations following single and multiple intradermal injections , with no safety signals 
identified . 
2.2 Scientific Rationale  
Based on the nonclinical and clinical data collected to date, MRG -201 is hypothesized to offer 
clinical benefit to patients with a history of keloid  formation .  In study MRG201-30-001, 
analysis of the Part A subjects demo nstrate d that endogenous miR-29b expression was  
downregulated and MRG-201 PD  biomarker expression was  modulated with cutaneous injury 
(e.g., incisional wounds).  Direct target genes of miR -29b that are implicated in multiple fibrotic 
diseases (e.g., multip le collagen genes) were upregulated following incision, and their expression 
inversely correlated with miR -29b expression.  Indirect, downstream targets that were previously 
determined to be upregulated by MRG-201 in mouse skin we re downregulated following 
incision (e.g., SDC4, SNX27).  A single administration of MRG -201 result ed in a 
downregulation of direct targets and an upregulation of downstream targets in a dose-dependent fashion, consistent with preclinical observations in m ice, rat s, and rabbits.  These studies support 
the use of the selected PD biomarkers and demonstrate the PD activity of MRG -201 in humans.  
Multiple administrations of MRG -201, administered either starting on Day 1 or on Day 4 
resulted in PD biomarker regulation (e.g., repression of collagen expression) and repression of normal fibroplasia both at the site of dosing and, in at least one-half of subjects, at a distal site.  
Though normal fibroplasia was decreased, MRG -201 did not adversely affect wound closure.  
These results indicat e that MRG -201 exerts anti-fibrotic effects in the skin and support its further 
clinical development for cutaneous fibrosis indications. 
The current protocol is a double-blind, placebo- controlled, multi-center, outpatient study 
designed to determine the safety, efficacy, and PK of MRG -201 compared with placebo when 
administered following excisional wound creation and suturing.  This study will provide further 
evidence regarding the safety and tolerability of MRG-201 in a patient population predisposed to 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 31 of 100 form ing keloids during wound healing and will investigate the activity of MRG-201 in reducing 
keloid formation over an approximately 1-year post-excision period. 
The dose selected for the first cohort in the proposed Phase 2a study is 5.3 mg MRG -201 ( active 
moiety ), or 0.09 mg/kg in a 60 kg adult. This dose corresponds to the maximum dose that can be 
administered using the injection method proposed for the initial cohort of subjects (four 20- µL 
injections around the perimeter of a sutured 6- mm excisional woun d). The initial dosing regimen 
will include 6 doses administered over 2 weeks analogous to the regimen used in the complet ed 
Phase 1 clinical trial in normal healthy volunteer s, in which subjects received doses as high as 
14 mg MRG -201 (s odium salt form), equivalent to 13 mg active moiety or 0.22 mg/kg in a 60 kg 
adult using the 2- week dosing regimen . The highest dose per linear centimeter  of incision in the 
Phase 1 study and the highest dose per linear centimeter of sutured excision in this protocol are 
equivalent (8.7 mg active moiety/cm incision vs. 8.8 mg active moiety/cm sutured excision). The 
results of nonclinical and clinical studies indicate that this dose and dosing regimen should be 
safe, well -tolerated and potentially efficacious in the prevention of keloid scar formation.  
The sponsor may enroll  up to 5 additional cohorts of approximately 12 subjects each to assess 
alternate doses and regimens. The dose may be decreased by reducing the dose volume or by dilution of the drug product solution. A lo nger duration of dosing, up to the 4-week duration used 
in GLP toxicology studies, may also be evaluated in subsequent cohorts at the 5.3 mg or lower dose levels.  Any cohort treated for longer than two weeks in the initial treatment cycle will not be elig ible for retreatment to avoid exceeding the maximum duration of dosing in GLP 
toxicology studies. The total exposure for any subject during the study will not exceed 12 doses of 5.3 mg MRG-201.  
2.3 Potential Risks and Benefits  
The potential risks and benefit of MRG -201 treatment are provided in the Investigator’s 
Brochure.  
2.3.1 Known Potential Risks  
The majority of published information regarding the observed nonclinical and clinical toxicity of oligonucleotide drugs relates to single-stranded phosphorothioate oligonucleotides.  Most of the observed side effects are believed to be hybridization-independent and related to the physical and chemical characteristics of this class of agents, including their relatively long plasma and tissue residence times.  MRG -201 includes two phosphorothioate linkages.  Its tissue and plasma 
clearance rates are significantly more rapid than that of many single-stranded phosphorothioate 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 32 of 100 oligonucleotides.  In GLP toxicology studies in rats and rabbits and in a Phase 1 clinical trial in 
humans, MRG-201 was not associated with some of the more common toxicological effects of this class (e.g., kidney and liver toxicity).   
Clinically, the most commonly observed side effects after systemic administration of 
phosphorothioate oligonucleotides ar e: 1) dermatological reactions at subcutaneous injection 
sites, 2) constitutional symptoms such as fever, chills, and myalgia primarily associated with 
initial doses, and 3) prolongation of activated partial thromboplastin time ( aPTT ) (when the 
drugs are g iven intravenously but not when administered subcutaneously).  In general, these 
effects are mild and transient, and resolve spontaneously. In the completed Phase 1 study in  normal healthy volunteers (Study  MRG 201-30-001), AEs 
associated with the injection  procedure, including reactions at the injection site ( edema, 
erythema, paresthesia, warmth, bruising, pain, pruritus) have been observed, with other common 
AEs including nasopharyngitis and headache. Intradermal injection of MRG -201 was associated 
with mild or moderate injection site edema or erythema in approximately one-third of subjects. 
These study drug- related adverse events occurred with a similar incidence following single or 
multiple injections of MRG -201. All these injection site reactions resolved without sequela, were 
of short duration, and did not recur or worsen in subjects that received multiple doses of MRG-201. There did not appear to be direct relationship between dose strength and incidence of TEAEs . 
Safety monitoring in clinical studies with MRG -201 includes assessments for typical 
class -related toxicities , including local tolerability at the injection site and systemic 
inflammation.  
2.3.2 Known Potential Benefits  
The completed  Phase 1 study in normal healthy volunteers was designed primarily to  evaluate 
safety  and local tolerability , with efficacy collected as an exploratory endpoint.  Preliminary 
evidence of PD activity as measured by gene expression changes and a reduction of fibroplasia 
following MRG-201 treatment has been observed and warran ts further investigation.  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 33 of 100 3 STUDY OBJECTIVES AND ENDPOINTS  
3.1 Objectives  
3.1.1 Safety Objective  
Investigate the safety and tolerability of multiple intradermal administrations of MRG -201 in 
subjects with a history of keloids. 
3.1.2 Pharmacodynamic Objective 
Investigate the activity of MRG -201 in prevention or reduction of keloid formation, in subjects 
with a history of keloid s. 
3.1.3 Other  Objectives 
•Evaluate additional pharmacodynamic endpoints of MRG-201 in subjects with a history of
keloids.
•Evaluate Patient Reported Outcomes.
•Characterize the pharmacokinetics of MRG -201 in subjects with a history of keloids.
3.2 Endpoints  
3.2.1 Safety  Endpoint s 
•The safety and tolerability of MRG -201 will be assessed by determining the incidence and
severity of clinically significant adverse events (i ncluding Grade 3 and 4 AEs, treatment-
related AEs, SAEs, and AEs requiring discontinuation of MRG-201), and physicalexamination findings, changes in vital signs, electrocardiograms (ECGs), and laboratoryparameters.
•AEs will be assessed according to the N ational Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE), version 5.0.
3.2.2 Pharmacodynamic Endpoint  
The formation of a keloid will be defined as a persistent scar that exhibits a score of at least 3 on 
the 
mVSS (Fearmonti et al 2010, see Appendix D), with a score of at least 1 in the height 
s
ub-domain.  For the purposes of this study, s cars that form at one or both of the bli nded wound 
sites f ollowing  the initi al treatment will be considered unconfirmed keloid(s) if the y exhibit a  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 34 of 100 score of 3 to 5 on the mVSS , with a score of at least 1 in the height sub- domain .  Unconfirmed 
keloid(s) with a score of 3 to 5 on the mVSS will be re- evaluated at the subsequent mont hly 
visits for up to 12 weeks.  K eloid(s) that persist after this 12 -week observation period and/or 
progress to an mVSS score of  ≥ 6 at any time  (with a score of at least 1 in the height 
sub-domain) will be considered confirmed keloid(s).  At th e time  of keloid confirmation , the 
investigator, in consultation with the subject, may elect to attempt local treatment of the keloid 
with triamcinolone as a standard of care therapy  after consultation with the sponsor. 
•Proportion of confirmed keloid formation at 2 4 weeks  across subjects for treated vs.
untreated lesions.
•Proportion of subjects with  improvement, which is defined as no confirmed keloid formation
in the treated lesion vs. confirmed keloid formation in the untreated lesion.
•Proportion of subjects forming confirmed keloids with MRG-201 treatment vs. placebo
treatment  at 12 weeks, 36 weeks, 52 weeks, and at the time of study withdrawal (if subjects
do not complete the study).
3.2.3 Other Pharmacodynamic  Endpoint s 
•Proportion of subjects forming confirmed keloids r egardless of treatment application .
•Time to keloid formation.
•Volume of keloid at 24 weeks , 52 weeks and at time  of triamcinolone injection (if
applicable) .
3.2.4 Exploratory Endpoint s 
•Modified Vancouver Scar Scale (mVSS; Fearmonti et al 2010 , see Appendix D) s core at  
visits occurring every 4 weeks from Day 29 to Day 365 after excisional wound creation.
•Patient
 and Observer  Scar Assessment Scale (P OSAS;  Appendix E) scores at visits occurring  
every 4 weeks from Day 29 to Day 365 after excisional wound creation.
•Keloid volume and 
keloid s everity (per mVSS in Appendix D and POSAS in Appendix E) at  
visits occurring every 4 weeks following a second 
cycle of dosing with MRG-201 or placebo  
in subjects  exhibiting evidence that a keloid may be forming at one or both biopsy sites 
within 12 weeks after
 initiation of the first cycle of study dosing. 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 35 of 100 3.2.5 Pharmacokinetic  Endpoint s 
•Plasma concentration of MRG -201 will be assessed at multiple time points on Day  1 and
Day 12 (or Day 26 for cohorts dosing for 4 weeks), and at single time points on Day 2 and
Day 13 (or Day 27 for cohorts dosing for 4 weeks). Voided urine samples for PK analyses
will also be collected on Day 1 and 12 (or Day 26 for cohorts dosing for 4 weeks) predoseand 3 hours postdose, and Day 2  and Day 13 (or day 2 7 for cohorts dosing for 4 weeks).
4 STUDY  DESIGN 
This is a  double-blind, placebo-controlled, multi-center, outpatient exploratory efficacy study in 
subjects with a high likelihood of keloid formation (i.e., history of ≥ 10 keloids  or history of 
large keloids, ≥ 4 cm) , with MRG-201 and placebo administered by intradermal injection around 
the site of two separat e punch biopsies. 
A minimum of 12 subjects are anticipated for enrollment in the first cohort of the study to attain at least 10 subjects who complete study participation  through 24 weeks after excisional wound 
creation.  Subjects who drop out for reasons other than safety or study treatment tolerability may 
be replaced with sponsor approval (up to 16 total including replacements).  The sponsor may enroll up to 5 additional cohorts of 12 to 16 subjects each (up to 80 total additional subjects) to assess lower  doses and/or  regimens.  
Subjects in the initial cohort will undergo a screening period lasting up to 28 days, followed by a 
double-blind, 12- day active treatment period (first cycle of study dosing) conducted in the 
outpatient setting , a possible second 12-day cycle of study dosing as outlined in Section 4.2, and 
a follow-up period of up to 52 weeks (± 7 days) after initiation of the first cycle of study dosing . 
Subjects in additional cohorts may receive lower doses or an extended 26- day active treatment 
period without the option to receive a second c ycle of treatment. Follow -up periods for those 
additional cohorts will remain unchanged. 
Subjects will be continuously monitored for s afety through evaluations of AEs , vital signs, 
physical examination findings, clinical laboratory measurements, and ECG mo nitoring. 
Samples will be collected for plasma PK on Days 1, 2, 12, and 13 ( or Days 1, 2, 26, and 27 for 
subjects receiving an initial 26 -day treatment cycle ). 
The punch biopsy wound sites will be evaluated for keloid formation, photographic assessment, 
and clinical response during the active treatment and follow-up periods of the study.  Biopsy 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 36 of 100 samples will be saved for future protein and/or nucleic acid analysis to assess MRG -201 effects 
in subjects who form keloids. 
4.1 Punch Biopsies  
On Day 1  of the study, subjects will be seen at the clinic in the morning to confirm study 
eligibility and for their baseline assessments, punch biopsy procedures, baseline photography of 
the biopsy sites, and administration of study treatments.  Subjects will undergo two 6- mm p unch 
biopsies bilaterally in the upper back/shoulder region in areas that can be covered with clothing and are likely to form  keloids.  The locations for the biopsies must be at least 10 cm from each 
other and far enough away from existing keloids that new keloid formation may  be assessed.  
The punch biopsy excisional wound sites will be closed with sutures.  
4.2  Treatments Administered  
Following completion of the punch biopsies on Day 1, one punch biopsy wound site will be 
treated with MRG -201 and the other wound site will be treated with placebo.  The treatment for 
each wound site will be randomized (left versus right) and blinded but consistent throughout 
dosing.  MRG -201 and placebo will each be administered as four 20-µL injections around one 
wound site , with subjects receiv ing approximately 5.3 mg of the MRG -201 active moiety on 
each dosing day (approximately 1.3 mg per 20-µL injection).  After all Day 1 assessments and procedures are complete, subjects will be discharged to home. 
Subjects will return to th e clinic on Days 3, 5, 8, 10, and 12 to receive repeat injections with the 
same blinded study treatment that was administered at each wound site on Day 1.  Subjects will 
return to the clinic on Day 19 for additional assessments and safety monitoring, and t he Principal 
Investigator ( PI) will determine whether any tolerability concerns are present and warrant 
consultation and safety data review with the sponsor’s Medical Monitor.  If at any point 
clinically significant safety or tolerability issues are observ ed by the investigator and are thought 
to be possibly related or related to MRG-201, the subject will not receive further administration of MRG -201 pending follow-up with the Medical Monitor.  In this event, the investigator must 
notify the sponsor’s Medical Monitor by email or phone within 24 hours, and a meeting with the sponsor Medical Monitor may be convened.  
On Day 8, Day 12, Day 19, Day 29 (4 weeks ± 3 days after completion of the punch biopsies) 
and then every 4 weeks for 1 year (Days 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365, each ± 7 days), excisional wound sites will be assessed for keloid formation, photographic evaluations, and other study assessments. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 37 of 100 For subjects receiving 6 doses of MRG- 201 in the initial treatment cycle, if the re is evidence that 
a keloid may be forming (defined as meeting a score of 1 or 2 on the mVSS and having an 
appearance consistent with an area likely to form a keloid according to investigator judgement ) 
within 12 weeks after initiation of the first cycle of study dosing, and following the initial 29- day 
treatment and assessment period, subjects will undergo a second cycle of study dosing in one or 
both biopsy sites (depending on keloid formation). Subjects will be treated with MRG -201 or 
placebo according to the original treatment assignments  (blinding will be maintained during the 
second treatment regimen) .  The treatment regimen for the second cycle of study dosing will be 
the same as  for the first cycle , i.e., an initial dose followed by additional doses 2, 4, 7, 9, and 
11 days after the initial dose, with follow -up visits at Day s 19 and 29 after the re-start of dosing.  
Following the visit that occurs 29  days after the start of the second cycle of study dosing, 
re-treated biopsy sites will be followed ac cording to the first cycle visit schedule.  If the wound 
site scar(s) progress to a n mVSS score of 3  to 5 (with a score of at least 1 in the height 
sub-domain) after the 12 -week observation period and/or to an mVSS score of ≥ 6 at any time 
(with a score of at least 1 in the height sub-domain) , the scar(s) will be considered confirmed 
keloid(s).  At the time of keloid confirmation , the investigator, in consultation with the subject, 
may elect to attempt local treatment of the keloid with triamcinolone as a standard of care 
therapy  after consultation with the sponsor. 
Additional cohorts may be enrolled to test lower doses or an extended dosing schedule.  Study procedures for the extended dosing cohorts will be identical to the cohort described above, with the following exceptions: 1) subjects in these cohorts may receive a total of 12 intradermal doses of MRG -201 and placebo on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26; 2) subjects will 
not undergo a second cycle of tre atment if the 4 -week dosing schedule is used; and 3) 
pharmacokinetic assessments will be performed on study Day 1, 2, 26, and 2 7 for subjects 
receiving an initial 26 -day treatment cycle . 
5 ENROLLMENT , DISCONTINUATION AND WITHDRAWAL  OF 
STUDY PARTICIPANT S 
5.1 Inclusion Criteria 
Individual s must meet all of the following inclusion criteria to be eligible for participation in this 
study.  
1. Must provide written informed consent (signed and dated), and any authorizations required 
by law , and be able to comply with all study requirements. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 38 of 100 2. Males or females, ≥ 18 years of age at the time of informed consent.   
3. Females must have a negative serum pregnancy test at screening and a negative urine 
pregnancy test on their first dosing day.  
4. Females must not be or planning to be pregnant or lactating during the study. Females must 
be post- menopausal (confirmed by follicle -stimulating hormone [FSH] test for subjects 
whose last menstrual cycle was within the last 2 years before screening ), abstinent, in a 
monogamous same sex relation ship, surgically sterile or, if of child bearing potential, must 
use two acceptable methods of contraception with at least one being a barrier method throughout their study participation and for at least 6 months following the last dose of study treatment .  Acceptable methods of contraception include oral, injectable or implantable 
hormonal contraception, intrauterine device,  or medically -confirmed vasectomized partner . 
5. Males must be surgically sterile, abstinent, or if engaged in sexual relations with a fe male of 
child -bearing potential, must be using two acceptable methods of contraception with at least 
one being a barrier method for at least 6 months following the last dose of study treatment.  Contraception for male subjects could include a condom and a highly effective second method during and for at least 6 months after the last dose of study treatment. 
6. Investigator feels that the subject is likely to form keloids in the upper back/shoulder area after punch biopsy based on a history of a high frequency of keloid formation (history of ≥ 10 keloids), or a history of large keloids (≥ 4 cm). 
7. Must have bilateral 2 cm × 2 cm areas, where skin punch biopsy may be performed in the upper back/shoulder region and can be covered by clothing, that are free of keloids, acne, striae or other skin pathologies or complications (e.g., tattoos, excessive hair) that may obstruct the ability to evaluate the biopsy sites.  
8. Subject is currently clinically stable and is likely to remain clinically stable for a minimum of 
14 months from s creening.  
9. Subject is not anticipated to require systemic corticosteroids during participation in the study.  
10. Must be able to communicate effectively with study personnel. 
5.2 Exclusion Criteria  
Individuals who meet any  of the following exclusion criteria are not to be enrolled in this study.  
1. Recent history of alcoholism (within the past 1 year). 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 39 of 100 2. History of drug abuse or use of illicit drugs (such as cocaine, methamphetamines, or heroin)
within 1 year prior to s creening.  Subjects must also agree to refrain from illegal drug use
during the study.
3.Systemic use of steroids within 4 weeks of Day 1, or local use of steroids within 1 week of
Day 1 .
4. An active or uncontrolled infection at screening or Day 1 .
5.Positive at the time of screening for human immunodeficiency virus ( HIV), Hepatitis B
(surface antigen), or Hepatitis C .
6. Liver dysfunction, as defined by alanine aminotransferase (ALT), aspartate amino transferase
(AST), bilirubin, or alkaline phosphatase > 1.5 × upper limit of normal ( ULN ) at screening or
Day 1 .
7. Renal dysfunction defined a s serum creatinine > 2 mg/dL at screening or Day 1 .
8.Clinically significant anemia, neutropenia , or thrombocytopenia at screening or Day 1.
9. History of bleeding diathesis or coagulopathy.
10. Genetic disorders that predispose to keloids. These include, among others, Ehlers -Danlos
syndrome, Ullrich congenital muscular dystrophy, and Rubenstein-Taybi syndrome.
11.Prior malignancies within the past 3 years (allowing squamous cell and basal cell carcinomas
with free margins at excision, or other malignancies considered cured by surgical resection).
12.Presence on ECG of QT interval corrected for heart rate using Fridericia’s formula (QTcF)> 450 msec or > 480 msec if concomitant bundle branch block, at screening or Day 1.
13. Use of an investigational small molecule drug during the 30 days prior to screening or use of
an investigational oligonucleotide or biologic drug during the prior 90 days.
14. History of allergy or severe adverse reaction to an oligonucleotide.
15. Unwillingness to comply with study procedures, including follow-up, as specified by this
protocol, or unwillingness to cooperate fully with the Investigator.
16.Clinically significant abnormalities in medical history, physical examination, or laboratory
values that, in the opinion of the Investigator, would make the subject unsuitable forinclusion in the study.
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 40 of 100 5.3 Participant Discontinuation or Withdrawal  
5.3.1 Reasons for Participant Discontinuation or Withdrawal  
Subjects may withdraw their consent to participate in the study at any time for any reason 
without prejudice to their fut ure medical care by the physician or at the institution.   If a subject 
withdraws consent, the date and stated reason for consent withdrawal should be documented.  
Subjects meeting any of the following criteria should discontinue study treatment: • Unacceptab le AE(s) or failure to tolerate study treatment; 
• Changes in the subject’s condition or development of an intercurrent illness that renders the 
subject unsuitable for further study treatment in the judgment of the Investigator; 
• Withdrawal of consent; 
• Pregna ncy (treatment will be discontinued but study observations may continue); 
• Subject is lost to follow -up; 
• Discretion of the Investigator; 
• Termination of the study by the Sponsor. 
5.3.2 Procedures for Participant Discontinuation or Withdrawal 
Wherever possible, the tests and evaluations listed for the post- treatment evaluation period  
should be carried out and an effort should be made to continue follow-up.  The Sponsor should be notified of all study withdrawals through the designated electronic case report forms ( eCRFs ) 
in a timely manner.  
Additional subjects may be enrolled in a given cohort (up to a total of 16 subjects in a cohort), i f 
fewer than 10 subjects complete study participation through 24 weeks for reasons other than the 
safety or tolerability of study t reatment , or if dosing is not completed per protocol for an 
individual subject for reasons other than the safety or tolerability of s tudy treatment . 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 41 of 100 6 STUDY PRODUCTS   
6.1 Study Product(s) Management  
6.1.1 Acquisition  
MRG -201 will be supplied by the Sponsor and sent to clinical study sites.   The study sites will 
provide placebo comparator (0.9% sodium chloride injection, United States Pharmacopeia 
[USP]).  
6.1.2 Formulation, Appearance, Packaging, and Labeling 
The MRG -201 Drug Product is manufactured according to current Good Manufacturing Practice 
(cGMP) regulations for use in clinical trials.  
The MRG -201 Drug Product is supplied as a sterile solution for injection.  The Drug Product is 
formulated in an isosmotic phosphate buffer, pH 7.4 ± 0.5, corresponding to 66 mg/mL of the  
active moiety.  The Drug Product is packaged in single- use glass vials with a rubber closure and 
an aluminum flip -off overseal, each containing 0.3 mL of a clear to  slightly yellow liquid 
formulation. 
6.1.3 Storage and Stability 
The MRG -201 Drug Product is stored at -20 ± 5°C , protected from light. 
6.1.4 Accountability  
The investigator is responsible for ensuring adequate accountability of all used and unused study 
treatment .  All drug supplies and associated documentation will be reviewed and verified by the 
Clinical Research Associate ( CRA ).  Unused material cannot be disposed of until approval is 
obtained from the CRA.  The study site is responsible for the disposal and/or destruction of all unused study treatment  supplies, according to the site’s standard operating procedures.  If the site 
cannot dispose of these materials, arrangements should be made between the site and Sponsor’s 
representative for destruction or return of the unused study treatment  supplies. 
6.2 Dosage, Preparation and Administration of Study Product s 
6.2.1 Dose and Regimen  
As outlined in Section  4.2, each subject will receive injections with MRG -201 and placebo 
around the site of two separate 6-mm punch biopsies.  The treatment for each wound site will be 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 42 of 100 randomized (left versus right) and blinded but consistent throughout dosing.  MRG -201 and 
placebo will each be administered as four 20-µL injections around one wound site , with s ubjects 
receiv ing approximately 5.3 mg of MRG-201 active moiety on each dosing day (approximately 
1.3 mg per 20- µL injection).  
Study treatment injections for subjects receiving 6 doses in their initial treatment cycle will be 
administered on Days 1, 3, 5, 8, 10, and 12 of the first cycle of study dosing . A second cycle of 6 
study treatment injections will be administered for subjects who exhibit evidence of keloid 
formation (defined as meeting a score of 1 or 2 on the mVSS and having an appearance consistent with an area likely to form a keloid according to investigator judgement ) within 
12 weeks after  initia tion of the first cycle of study dosing and following the initial 29 -day 
treatment and assessment period . The treatment regimen for the second cycle of study dosing 
will be the same as  for the first cycle, i.e.,  an initial dose on Day 1 followed by additional doses 
on Days 3, 5, 8, 10, and 12, with follow- up visits at Day s 19 and 29 after the re-start of dosing.  
Subjects in additional optional cohorts may receive blinded study treatment injections on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and will not be given a second cycle of dosing.  
6.2.2 Method of Assignment to Treatment  
Subjects will be enrolled sequentially, starting with the first study cohort.  The treatment for each 
wound site will be randomized (left versus right), such that all subjec ts will receive  both 
MRG -201 and placebo in a double-blinded fashion. 
6.2.3 Dose Preparation  and Administration 
MRG -201 must be prepared in accordance with local pharmacy practices using aseptic 
technique.  Complete details on the preparation and administration of study treatment are 
provided in a separate Pharmacy Manual.  
6.2.4 Assessment of Treatment Adherence  
All study treatments will be administered at the investigational site by qualified study personnel.  
6.2.5 Dose Modifications or Delays 
Allergic events and/or inject ion-related toxicities should be managed according to institutional 
guidelines.  If institutional guidelines are not available, the following recommendations apply.  
Rash, pruritus, urticaria and wheezing may be treated with diphenhydramine hydrochloride and/or steroids as clinically appropriate.  Anaphylaxis or anaphylactoid signs or symptoms may 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 43 of 100 be treated with steroids and/or epinephrine as clinically indicated.  Subjects should be treated in a 
facility equipped for cardiopulmonary resuscitation.  Inject ion-related reactions (fever, rigors) 
should be treated per institutional guidelines but may be treated with acetaminophen and diphenhydramine hydrochloride. 
6.3 Prior and Concomitant Medications 
All medications (including over-the-counter medicines, herbal treatments, supplements, and 
vitamins) administered 30 days before the first administration of study treatment (Day 1) through 
the end of the study will be recorded on the eCRF, using generic names when possible.  
Systemic use of steroids is not permitted within 4 weeks of Day 1, and local use of steroids is not 
permitted within 1 week of Day 1. Systemic or local corticosteroids are not permitted during the 
first 12 weeks of study conduct. If an adverse event requires corticosteroid use, the investigator 
must contact the Medical Monitor to discuss the intervention and plans for continued subject 
participation. After 12 weeks, corticosteroids may be allowed after discussion with the M edical 
Monitor. 
7 STUDY PROCEDURE S 
The procedures and assessments that are outlined in this section will be performed at the time points specified by study visit in  Section 8 and summarized in Appendix A  (Schedule of Events, 
First Cycle  of Study Dosing) and Appendix B  (Schedule of Events, Second  Cycle  of Study 
Dosing). 
Written informed consent must be provided by each subject prior to the initiation of any study 
procedure or assessment that is not part of standard of care. 
7.1 Clinical Assessment s 
7.1.1 Medical History  
Medical history will be recorded  at screening .  Any ongoing conditions and signs and symptoms 
observed prior to first dose of study treatment should be recorded as medical history. 
7.1.2 Vital Signs  
Vital signs (blood pressure, heart rate,  respiratory rate, and body temperature) will be measured 
at screening and at the time points indicated in Appendix A , Appendix B , and Appendix C . 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 44 of 100 7.1.3 Physical Examination 
A complete physical examination  will be performed by trained medical personnel at s creening 
and on Day 1 of each cycle of study dosing.  Brief symptom- directed physical examinations 
should be performed at the subsequent time points specified in  Appendix A , Appendix B  and 
Appendix C.  Weight will be documented only at s creening, on Days 12 and 85 of the first cycle 
of study dosing (Day 26 and 85 if receiving 12 doses of blinded study treatment) and Day 12 of 
the second cycle of study dosing (if applicable) , and at the end of the study (Day  365). 
7.1.4 Prior and Concomitant Medications  
All medications (including over-the-counter medicines, herbal treatments, supplements, and vitamins) administered 30 days before the first administration of study  treatment through the end 
of the study will be recorded.  
7.2 Safety Assessments 
7.2.1 Adverse Events  
AEs will be assessed at each study visit by direct obser vation and subject  interviews.  The 
severity of AEs will be evaluated using the NCI CTCAE, version 5.0.  All AEs that occur from initiation of study treatment through 30 days after the last dose of study treatment must be 
recorded, regardless of causal ass essment to study treatment.  
7.2.2 Clinical Laboratory Assessments  
Blood or urine s amples will be collected for the following clinical laboratory measurements at 
screening to determine eligibility and predose at each time point indicated in  Appendix A , 
Appendix B , and Appendix C.  Clinical laboratory assessments do not need to be performed on 
Day 1 of the study if screening laboratory measurements were performed within 3 days prior to 
Day 1.  
• Hematology  
• Clinical chemistry  
• Urinalysis (including microscopy)   
In addition, s creening for HIV, hepatitis B, and hepatitis C will be performed during s creening.   
Female subjects who are not surgically sterile or have had last menstrual period > 2 years from 
screening date will also undergo FSH testing during screening to confirm menopause. 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 45 of 100 7.2.2.1  Pregnancy Test 
Female subjects must have a negative serum pregnancy test at screening and negative urine 
pregnancy tests at the subsequent  time points specified in Appendix A and Appendix B.  A 
positive pregnancy test will result in imme diate di scontinuation  of study tr eatment ; howe ver, 
study a ssessments w ill continue  to evaluate study endpoint s.  All pregnancies w ill be  followed 
thr
ough to outcome. 
7.2.3 Elect
rocardiograms  
Single 12- lead ECGs  will be  performed at screening and on Days 1 (predose) , 2, and 12 
(predose) of each cycle of study dosing (or Day 26, predose, in subjects receiving 12 doses of 
blinded study treatment in the first cycle) , as spec ified in  Appendix A , Appendix B  and 
Appendix C .  Electrocardiogram  parameters to be evaluated include the RR, QT, QRS, and PR 
intervals.  In addition, Fridericia’s formula should be used to calculate the QT interval corrected 
for heart rate (QTcF).  Abnormal ECG measurements will be recorded as AEs only if they are 
considered to be clini cally significant by the investigator.  
7.3 Pharmacokinetic  Sampling  
Plasma samples to measure MRG -201 concentrations will be collected on Days 1, 2, 12 and 13 
(or Days 1, 2, 26, and 27 for subjects receiving an initial 26 -day treatment cycle  ) of the first 
cycle of study dosing at the pre- and postdose time points specified in Appendix A  and 
Appendix C . Voided urine samples for PK analyses will also be collected on Day 1 and Day 12 
(or Da y 26 for cohorts dosing for 4 weeks) predose and 3 hours postdose, and Day 2  and Day 13 
(or day 2 7 for cohorts dosing for 4 weeks). 
7.4 Pharmacodynamic  Assessments  
7.4.1 Punch Biops ies 
On Day 1  of the first cycle of study dosing, subjects will undergo two 6-mm punch biopsies 
bilaterally in the upper back/shoulder region in areas that can be covered with clothing and are likely to form  keloids.  For the purposes of this protocol, the upper back/shoulder region is 
defined as  the area from T3 to the inferior angle of th e scapula and extending 10 cm from the 
midline of the back.  The biopsy area is depicted in Figure 2. The  locations for the biopsies must 
be at least 10  cm from each other and far enough away from existing keloids that new keloid 
formation may  be assessed.  The biopsies will be performed bilateral ly in 2 cm × 2 cm areas 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 46 of 100 where there are no skin lesions or markings (e.g. tattoos) that could affect keloid assessment.  
The punch biopsy excisional wound sites will be closed with sutures.  Detailed instructions for 
the punch biopsy will be provided in the Study Manual. 
Figure 2: Pictorial Guide to Punch Biopsy Locations 
 
 
 
7.4.2 Physician Assessment  of Keloid Formation 
Excisional wound sites will be e valuated by the investigator for keloid formation (predose on 
dosing days) at the time points outlined in  Appendix A  and Appendix B , utilizing the mVSS and 
POSAS scales .  
The formation of a keloid will be defined as a persistent scar that exhibits  a score of at least 3 on 
the mVSS  (Fearmonti et al 2010,  see Appendix D ), with a score of at least 1 in the height 
sub-domain.  For the purposes of this study, s cars that  form at one or both of the blinded wound 
sites following the initial treatment will be considered unconfirmed keloid(s)  if they exhibit a 
score of 3 to 5 on the mVSS , with a score of at least 1 in the height sub-domain .  Unconfirmed 
keloid(s) with a score of 3 to 5 on the mVSS will be re- evaluated at the subsequent monthly 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 47 of 100 visits for up to 12 weeks.  K eloid(s) t hat persist after thi s 12- week observation period and/or 
progr
ess to an mVSS s core of  ≥ 6 at any time (w ith a score of at l east  1 in the height  
sub-
domain) will be considered confirmed keloid(s).  A t the time of keloid confirmation, the 
inve
stigator, in c onsultation  with the  subject, ma y e lect to a ttempt local treatment of  the keloid 
w
ith triamcinolone  as a s tandard of  care  therapy after consultation with the sponsor . 
7.4.2.1 M odified Vancouver S car S cale 
The mV
SS is a common tool for the assessment of keloid formation and will be used as the basis 
for defining keloid formation in this study. S cars observed at the biopsy wound sites will be 
evaluated and scored according to the mVSS (Fearmonti et al 2010, s ee Appendix D) at the t ime 
points outlined in Appendix A, Appendix B, and A ppendix C . 
7.4.2.2 T he Patient an d Observer S car A ssessment S cale 
The POSAS v2.0 consists of two pa rts: a Patient Scale and an Observer Scal e. Both scales 
contain s ix items t hat ar e scored num erically on  a ten-step s cale. Together t hey m ake up  the 
‘Total S core’ o f the Patient  and Observer S cale.   Category box es are available to s core nomina l 
parameters ( e.g. t ype of  color). Moreover, the patient and observe r also score their ‘ Overall 
Opinion’. Scars observed at the biopsy wound sites will be evaluated and scored according to the 
Patient S cale and  Observer S cales  (Appendix E) of the POSAS , at the time poi nts out lined in 
Appendix A, Appendix B, and Appendix C . 
7.4.3 Pat
ient Reported Outcome  
The Dermatology Life Quality Index (DLQI) will be completed as an exploratory Patient 
Reported Outcome to evaluate how much keloid scar formation has affect ed the subject’s quality 
of life.  The DLQI will be assessed at baseline and at about 6 and 12 months after the start of 
treatment.  Assessments will be completed at Day 1, Da y 8, Day 169 (24 weeks), and Day 365 
(52 weeks).  
7.4.4 Biopsy Wound Site  Photography 
During the first cycle of study dosing, biopsy wound sites will be photographed after completion 
of the biopsy on Day 1 and predose, as applicable, a t the time points  outlined  in Appendix A , as 
well as at the time the investig ator suspects a keloid may be forming, at the time of observation 
of an unconfirmed keloid, and at the time of keloid confirmation.  During the second cycle of 
study dosing (if applicable) , biopsy wound sites will be photographed before study dos ing on 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 48 of 100 Day 1 and  subsequently as outlined in Appendix B .  Detailed instructions for  photography will 
be provided in the Study Manual . 
7.5 Pharmacodynamic  Biomarker s 
Serum for anti-drug antibody analysis will be collected on Days  1, 12 (15 for 26 -day dosing), 29, 
85, and 169 of the first cycle of study dosing. 
7.6 Specimen Preparation, Handling, and Shipping  
Site-specific handling instructions for blood, tissue, and urine samples will be  provided in a 
separate Laboratory Manual.  
8 STUDY SCHEDULE  
Before recruitment of subject s into the study, written  Institutional Review Board ( IRB) approval 
of the protocol, informed consent and any additional subject information must be obtained. 
8.1 Screening  Period  (Day -28 to Day 0)  
During screening, a unique number will be assigned to each subject who signs informed consent 
for the study.  Once a subject is in screening or is enrolled in the study, s/he will only be 
identified by the assigned identification number.  
The following procedures and assess ments will be pe rformed during the screening period, which 
may last up to 28 days from the time a subject signs the IRB -approved informed consent form 
(ICF) . 
• Obtain informed consent of potential participant verified by written signature on an ICF.  
• Record medical history.   
• Record prior and concomitant medication s taken from 30 days prior to the first dose of 
study treatment.  
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a complete physical examination  (including documentation of weight).  
• Perform a single 12 -lead ECG.  
• Collect blood for the following: 
o Screening for HIV, hepatitis B,  and hepatitis C ; 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 49 of 100 o Confirmation of menopause by FSH (females who are not surgically sterile  or last 
menstrual period is >2 years from screening dat e); 
o Serum pregnancy test  (females) ; 
o Hematology ; 
o Clinical chemistry . 
• Collect urine for urinalysis. 
• Confirm eligibility of medical history and laboratory measurements according to 
inclusion/exclusion criteria.  
8.2 First Cycle of Dosing with MRG -201 and Placebo with 6 Doses for 
Initial Treatment Cycle  
Study assessments to be performed during the first cycle of study dosing are summarized in Appendix A . 
8.2.1 Day 1 (First Day of Study Treatment Administration) 
• Complete DLQI  
• Verify inclusion/exclusion criteria . 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a complete physical examination.  
• Collect blood for the following: 
o Hematology ( predose; only if s creening measurement was performed > 3 days be fore 
Day 1) ; 
o Clinical chemistry ( predose; only if s creening measurement was performed > 3 days 
before Day  1); 
o Antibody analysis; 
o PK (1 hour [ ± 10 minutes ], 2 hours [ ± 15 minutes ], and 3 hours [ ± 15 minutes] 
postdose). 
• Collect urine (predose) for urinalysis (on ly if screening measurement was performed 
> 3 days before Day  1) and pregnancy test  (females) . 
• Perform a single 12 -lead ECG ( predose
). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 50 of 100 • Obtain two 6 -mm punch biops ies and suture the resulting excisional wounds. 
• Photograph biopsy sites (post-biopsy and suture ). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
8.2.2 Day 2 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a single 12 -lead ECG ( approximately 24 hours after Day 1 dosing ). 
• Collect blood for the following: 
o PK (24 ±  4 hours after Day 1 dosing); 
o Hematology ; 
o Clinical chemistry . 
• Collect urine for urinalysis. 
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the i nvestigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.2.3 Days 3 and 5  
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the time of keloid confirmation. 
8.2.4 Day 8 
• Complete DLQI . 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 51 of 100 • Perform a brief, symptom -directed physical examination.  
• Collect blood (predose) for the following: 
o Hematology ; 
o Clinical chemistry . 
• Collect urine (predose) for urinalysis. 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.2.5 Day 10 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination.  
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the time of keloid confirmation . 
8.2.6 Day 12 
• Obtain vital signs (blood pressure, heart rate, respiratory rate,  and body temperature). 
• Perform a brief, symptom -directed physical examination  (including documentation of 
weight) . 
• Perform a single 12 -lead ECG ( predose ). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 52 of 100 • Collect blood (predose) for the following: 
o Hematology ; 
o Clinical chemistry ; 
o Antibody analysis; 
o PK (1 hour [ ± 10 minutes], 2 hours [ ± 15 minutes], and 3 hours [ ± 15 minutes] 
postdose). 
• Collect urine for PK 3 hours after dose (± 1 hour). 
• Collect urine (predose) for urinalysis and pregnancy test (females).  
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.2.7 Day 13 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Collect blood for PK (24 ±  4 hours after Day 12 dosing). 
o Collect urin e for PK (24 ± 4 hours after Day 12 dosing). 
• Review and record AEs and concomitant medications. 
8.2.8 Day 19 (± 2 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate,  and body temperature). 
• Perform a brief, symptom -directed physical examinatio n. 
• Collect blood for the following: 
o Hematology ; 
o Clinical chemistry . 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 53 of 100 • Collect urine for urinalysis. 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.2.9 Day 29 (± 3 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical exami nation. 
• Collect blood for the following: 
o Hematology ; 
o Clinical chemistry ; 
o Antibody analysis. 
• Collect urine for urinalysis and pregnancy test (females). 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites.  
• Review and record AEs and concomitant medications. 
8.2.10 Days 57, 113, 141, 197, 225, 281, 309, 337 (± 7 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2 010, see Appendix D  and 
Appendix E ). 
• Review and record AEs and concomitant medications. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 54 of 100 • Note: Biopsy wound sites are to  be photographed at the time the investigator suspe cts a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation. 
8.2.11 Day 85 (± 7 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination  (including documentation of 
weight) . 
• Collect blood for the following: 
o Hematology ; 
o Clinical chemistry ; 
o Antibody analysis. 
• Collect urine for urinalysis and pregnancy test (females).  
• Perform physician assessment of keloid formation an d volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites.  
• Review and re cord AE s and concomitant medications. 
8.2.12 Days 169 and 253 (± 7 Days) 
• Complete DLQI (Day 169 only). 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination.  
• Collect blood for the following: o Hematology ; 
o Clinical chemistry ; 
o Antibody analysis (Day 169 only). 
• Collect urine for urinalysis. 
• Perform physician assessment of keloid formation and volume. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 55 of 100 • Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites. 
• Review and record AEs and concomitant medications. 
8.3 Second Cycle of Dosing with MRG -201 and /or Placebo 
For subjects receiv ing 6 doses of MRG- 201 in the initial treatment cycle, if there is evidence that 
a keloid may be forming (defined as meeting a score of 1 or 2 on the mVSS and having an 
appearance consistent with an area likely to form a keloid according to investigator judgement ) 
within 12 weeks after initia tion of the first cycle of study dosing, and following the initial 29- day 
treatment and assessment period, subjects will undergo a second cycle of study dosing in one or 
both biopsy sites (depending on keloid formation).  Subjects will complete the procedures that 
were planned at the scheduled visit (e.g. , Day 85 visit procedures, if that is the current visit), as 
well as be treated with  MRG -201 or placebo according to the original ly assigned  study 
treatment s.  The study assessments to be performed during the second cycle of study dosing are 
summarized in  Appendix B . 
8.3.1 Day 1 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a complete physical examination  (including documentation of weight). 
• Collect blood for the following: 
o Hematology  (predose); 
o Clinical chemistry  (predose) . 
• Collect urine (predose) for urinalysis and pregnancy test (females).  
• Perform a single 12 -lead ECG ( predose ). 
• Photograph biopsy sites ( predose ). 
• Perform physician assessment of keloid formation. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Administer intradermal study treatment(s). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 56 of 100 • Review and record AEs and concomitant medications. 
8.3.2 Day 2 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a single 12 -lead ECG ( approximately 24 hours after Day 1 dosing ). 
• Collect blood for the following: 
o Hematolog y; 
o Clinical chemistry . 
• Collect urine for urinalysis. 
• Perform physician assessment of keloid formation. 
• Review and record AEs and concomitant medications. 
8.3.3 Days 3 and 5 
• Obtain vital signs (blood pre ssure, heart rate, respiratory rate, and body temperature).  
• Perform physician assessment of keloid formation (predose). 
• Administer intradermal study treatment(s). 
• Review and record AEs and concomitant medications. 
8.3.4 Day 8 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature).  
• Perform a brief, symptom -directed physical examination.  
• Collect blood (predose) for the following: 
o Hematology ; 
o Clinical chemistry . 
• Collect urine (predose) for urinalysis. 
• Perform physician assessment of keloid formation  and volume (predose). 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 57 of 100 • Administer intradermal study treatment(s). 
• Review and record AEs and concomitant medications. 
8.3.5 Day 10 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform physician assessment of keloid formation (predose). 
• Administer intradermal study treatment(s). 
• Review and record AEs and concomitant medications. 
8.3.6 Day 12 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination (including documentation of 
weight) . 
• Perform a single 12 -lead ECG ( predose ). 
• Perform physician assessment of keloid formation and volume (predose). 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Administer intradermal study treatment(s). 
• Review and record AEs and concomitant medications. 
8.3.7 Day 19 (± 2 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature ). 
• Perform a brief, symptom -directed physical examination.  
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Review and record AEs and concomitant medications. 
8.3.8 Day 29 (± 3 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 58 of 100 • Perform a brief, symptom -directed  physical examination.  
• Collect blood for the following: 
o Hematology ; 
o Clinical chemistry . 
• Collect urine for urinalysis and pregnancy test (females). 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites. 
• Review and record AEs and concomitant medications. 
8.3.9 Subsequent Visits, Every 4 We eks (± 7 Days) 
Following the visit that occurs 29 days after the start of the second cycle of study dosing, 
re-treated biopsy sites will be followed according to the first cycle  visit schedule (see 
Section  8.2.10 [Days  57, 113, 141, 197, 225, 281, 309, and  337], Section  8.2.11 [Day  85], and 
Section  8.2.12 [Days  169 and 253]). 
8.4 Dosing with MRG -201 and Placebo with 12 Doses for a Single  
Treatment Cycle  
Study assessments to be performed during the single  26-day cycle of study dosing are 
summarized in  Appendix C . 
8.4.1 Day 1 (First Day of Study Treatment Administration) 
• Complete DLQI . 
• Verify inclusion/exclusion criteria.  
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a complete physical examination.  
• Perform a single 12 -lead ECG ( predose ). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 59 of 100 • Collect blood for the following: 
o Hematology ( predose; only if screening measurement was performed > 3 days before 
Day 1) ; 
o Clinical chemistry ( predose; only if s creening measurement was performed > 3 days 
before Day  1); 
o Antibody analysis; 
o PK (1 hour [ ± 10 minutes], 2 hours [ ± 15 minutes], and 3 hours [ ± 15 minutes] 
postdose). 
• Collect urine (predose) for urinalysis (only if s creening measurement was performed 
> 3 days before Day  1) and pregnancy test (females).  
• Obtain two 6-mm punch biopsies. Suture. 
• Photograph biopsy sites (post-biopsy). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
8.4.2 Day 2 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a single 12 -lead ECG ( approximately 24 hours after Day 1 dosing ). 
• Collect blood for the following:  
o PK (24 ±  4 hours after Day 1 dosing); 
o Hematology ; 
o Clinical chemistry . 
• Collect urine for urinalysis and PK (24 ± 4 hours after Day 1 dosing). 
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the ti me the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 60 of 100 8.4.3 Days 3, 5, 10, 12, 17, 19 and 24 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body t emperature).  
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.4.4 Day 8 
• Complete DLQI . 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination.  
• Collect blood (predose) for the following:  
o Hematology ; 
o Clinical chemistry . 
• Collect urine (predose) for urinalysis. 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspe cts a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the time of keloid confirmation . 
8.4.5 Days 15 and 22 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 61 of 100 • Collect blood (predose) for the following: 
o Hematology ; 
o Clinical chemistry ; 
o Antibody analysis. 
• Collect urine (predose) for urinalysis (Day 15 only). 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS sc oring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications.  
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.4.6 Day 26 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature).  
• Administer intradermal study treatments.  
• Review and record AEs and concomitant medications. 
• Collect blood (predose) for PK  (1 hour [ ± 10 minutes], 2 hours [ ± 15 minutes], and 
3 hours [ ± 15 minutes] postdose). 
• Collect urine for PK 3 hours after dose (± 1 hour). 
• Note: Biopsy wound sites are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the time of keloid conf irmation . 
8.4.7 Day 27 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Collect blood for PK (24 ±  4 hours after Day 26 dosing). 
• Collect urine for PK (24 ± 4 hours after Day 26 dosing). 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 62 of 100 • Review and record AEs and concomitant medications . 
8.4.8 Day 29 (± 1 Day) 
• Obtain vital signs and weight (blood pressure, heart rate, respiratory rate, and body 
temperature).  
• Perform a brief, symptom -directed physical examination.  
• Perform a single 12 -lead ECG . 
• Collect blood for the following: 
o Hemat ology; 
o Clinical chemistry ; 
o Antibody analysis. 
• Collect urine for urinalysis and pregnancy test (females) . 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites.  
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sites are to  be photographed at the time the investig ator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation . 
8.4.9 Day 36 (± 2 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Review and record  AEs and concomitant medications. 
8.4.10 Days 57, 113, 141, 197, 225, 281, 309, 337 (± 7 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform physician assessment of keloid formation and volume. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 63 of 100 • Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Review and record AEs and concomitant medications. 
• Note: Biopsy wound sit es are to  be photographed at the time the investigator suspects a 
keloid may be forming, at the time of observation of an unconfirmed keloid, and at the 
time of keloid confirmation. 
8.4.11 Day 85 (± 7 Days) 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination  (including documentation of 
weight) . 
• Collect blood for the following: 
o Hematology ; 
o Clinical chemistry ; 
o Antibody analysis. 
• Collect urine for urinalysis and pregnancy test (f emales).  
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites.  
• Review and record AEs and concomitant medications. 
8.4.12 Days 169 and 253 (± 7 Days) 
• Complete DLQI (Day 169 only). 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, s ymptom- directed physical examination.  
• Collect blood for the following: o Hematology ; 
o Clinical chemistry ; 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 64 of 100 o Antibody analysis (Day 169 only). 
• Collect urine for urinalysis. 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring ( Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites. 
• Review and record AEs and concomitant medications. 
8.5 End of Study Visit  (Day 36 5 ± 7 Days)  
The end of study assessments will be performed on Day 365 (± 7 days) . For subjects who 
discontinue treatment early , the end of study assessments should be performed at the final study 
visit (assuming the subject has not withdrawn consent). 
• Complete DLQI . 
• Obtain vital signs (blood pressure, heart rate, respiratory rate, and body temperature). 
• Perform a brief, symptom -directed physical examination (including documentation of 
weight).  
• Collect blood for the following: 
o Hematology ; 
o Clinical chemistry . 
• Collect urine for urinalysis and pregnancy test (females). 
• Perform physician assessment of keloid formation and volume. 
• Assign mVSS and POSAS scoring (Fearmonti et al 2010, see Appendix D  and 
Appendix E ). 
• Photograph biopsy sites. 
• Review and record AEs and concomitant medications. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 65 of 100 9 ASSESSMENT OF SAFETY 
9.1 Specification of Safety Parameters  
Safety will be evaluated through continuous monitoring of AEs, vital signs, physical 
examinations, clinical laboratory measurements, and ECGs.  
9.2 Definition of Adverse Event s  
9.2.1 Adverse Event  
An AE  is any untoward medical occurrence whether or not considered drug related.  An AE can 
be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug and does not imply any judgment about causality.  An AE can arise with any use of the drug (e.g., off-label use, use in combination with 
another drug) and with any route of administration, formulation, or dose, including an overdose.  
9.2.2 Suspected Adverse Reaction  
A suspected adverse reaction is any AE for which there is a reasonable possibility that the drug 
caused the AE.  For the purposes of Investigational New Dru g (IND) safety reporting, 
‘‘reasonable possibility’’ means there is evidence to suggest a causal relationship between the drug and the AE.  Suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any AE caused by a drug . 
9.2.3 Life-Threatening AE or Life- Threatening Suspected Adverse Reaction  
An AE or suspected adverse reaction is considered ‘‘life- threatening’’ if, in the view of either the 
Investigator or Sponsor, its occurrence places the subject  at immediate risk of death.  It does not 
include an AE or suspected adverse reaction that, had it occurred in a more severe form, might 
have caused death. 
9.2.4 Serious AE or Serious Suspected Adverse Reaction  
An AE or suspected adverse reaction is considered ‘‘serious’’ if, in the view of either the 
Investigator or Sponsor, it results in any of the following outcomes:  
• Death.  
• A life -threatening AE (see Section 9.2.3).  
• Requires prolongation of existing hospitalization. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 66 of 100 • A persistent or significant disability or incapacity or substantial disruption of the ability 
to conduct normal life functions. 
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject  and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events i nclude allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not resul t in 
inpatient hospitalization.  
9.2.5 Unexpected AE or Unexpected Suspected Adverse Reaction  
An AE or suspected adverse reaction is considered ‘‘unexpected’’  if it is not listed in the 
Reference Safety Information in the Investigator ’s Brochure or is not listed at the specificity or 
severity that has been previously observed .  
For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the Investigator ’s Brochure referred only to elevated hepatic enzymes or hepatitis.  
Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the Investigator ’s Brochure listed only cerebral vascular accidents.  
‘‘Unexpected,’’ as used in this definition, also refers to AEs or suspected adverse reactions that are mentioned in the Investigator ’s Brochure as occurring with a class of drugs or as anticipated 
from the pharmacological properties of the drug but are not specifically mentioned as occurring with the particular drug under investigation. 
9.3 Adverse Event Classification  
9.3.1 Relationship to Investigational Product   
The Investigator’s asses sment of causality must be provided for all adverse events (serious and 
non-serious).  An Investigator’s causality assessment is the determination of whether there exists a reasonable possibility that the investigational product caused or contributed to an AE.  
• Not related:  The AE is clearly not related or is unlikely to be related to the study therapy.  
The temporal relationship of the onset of the AE relative to administration of the product is not reasonable, or the AE can be explained by another cause s uch as an underlying 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 67 of 100 medical condition or other concomitant medication , or the adverse event has no plausible 
relationship to study therapy. 
• Related :  The AE is related to the study therapy.   The temporal relationship of the AE to 
administration of the product is reasonable and there is no other cause to explain the 
event.  AEs should be classified as related if the investigator feels there is evidence to 
suggest a causal relationship between the drug and the adverse event . 
9.3.2 Severity  
All adverse events enter ed into the eCRF will be graded for severity using the NCI CTCAE, 
version 5.0.  If an adverse event is not listed in the CTCAE version 5.0, then the Investigator will use the terms:  Mild, Moderate, Severe, Life-threatening , or Death  to describe the maximu m 
intensity of the adverse event.  For purposes of consistency, these intensity grades are defined as 
follows: 
Severity  Definition  
Grade 0  No change from Normal or Reference Range 
Grade 1 (Mild)  No limitation of usual activities.  
Grade 2 (Moderate)  Some  limitation of usual activities.  
Grade 3 (Severe)  Inability to carry out usual activities.  
Grade 4 (Life -threatening)  Immediate risk of death.  
Grade 5 ( Death ) Resulting in death.  
9.4 Collection and Reporting of Adverse Events  
9.4.1 Initial Reporting of Adverse Events  
Subject s will be evaluated and questioned generally to identify adverse events during the course 
of the study.  Any events occurring prior to administration of the first dose of study treatment 
will be recorded on the Medical History eCRF.  Events oc curring after administration of the first 
dose of study treatment or those that increase in severity or frequency will be recorded as treatment -emergent AEs on the Adverse Event e CRF.  Adverse events that occur up to and 
including 30 days after administration of the last dose of study treatment must be reported. 
All AEs spontaneously reported by the participant and/or in response to an open question from 
study personnel or revealed by observation, physical examination, or other diagnostic procedures will be  recorded on the Adverse Event e CRF.  Any clinically relevant deterioration in laboratory 
assessments or other clinical findings, as assessed by the Investigator, is considered an AE and 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 68 of 100 must be recorded on the Adverse Event e CRF.   In addition, an abnormal test finding will be 
classified as an adverse event if one or more of the following criteria are met:  
• The test finding is accompanied by clinically significant symptoms.  
• The test finding necessitates additional diagnostic evaluation(s) or medical/surgic al 
intervention; including additional concomitant drug treatment or other therapy.  Note: 
simply repeating a test finding, in the absence of any of the other listed criteria, does not 
constitute an AE.  
• The test finding leads to a change in study treatment dosing or discontinuation of subject  
participation in the clinical research study.  
• The test finding is considered an AE by the Investigator.  
Wherever possible, a specific disease or syndrome rather than individual associated signs and symptoms should be identified.  However, if an observed or reported sign or symptom is not 
associated with a documented disease or syndrome, the sign or symptom should be recorded as a separate AE.  Laboratory data are to be collected as stipulated in this protocol.  Clinic al 
syndromes associated with laboratory abnormalities are to be recorded as appropriate (e.g., diabetes mellitus rather than hyperglycemia).  
9.4.2 Follow- up of Adverse Events  
All AEs considered to be related to study treatment will be followed until resolution or stabilization .  
9.5 Collection and Reporting of  Serious Adverse Events  
9.5.1 Initial Serious Adverse Event Reports  
All SAEs that occur up to and including 30 days after administration of the last dose of study 
treatment  must be reported by the Investigator to the Sponsor or Sponsor’s designee within 
24 hours of awareness of the event  by submission of a SAE Notification Form.  Investigators 
must report to the Sponsor any SAE , whether or not considered drug related, including those 
listed in the protocol or Investiga tor’s Brochure.  The initial report must contain at a minimum a 
subject  identifier code, an event term, and an assessment of causality.  T he SAE Notification 
Form should be e- mailed to: 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 69 of 100  
 
 
If t
he Investigator is unable to complete and send the SAE Notification Form within the 
timeframe required, the SAE must be reported via phone call to: 
Prima ry Contact   
       
 
                       
                   
 
Back -up Contact s  
  
  
  
  
  
  
   
 
An Investigator may be requested by the Sponsor to obtain specific follow-up information in an 
expedited fashion.  This information may be more detailed than that captured on the Adverse 
Event e CRF.   In general, this will include a description of the S AE in sufficient detail to allow 
for a complete medical assessment of the case and independent determination of possible causality.  Information on other possible causes of the event, such as concomitant medications 
and illnesses must be provided.  In the case of a subject  death, a summary of available autopsy 
findings must be submitted as soon as possible to the Sponsor or the Sponsor’s designated representative.  
9.5.2 Follow- up of Serious Adverse Events  
All SAEs should be followed up until resol ution or stabilization .  The timelines and procedure 
for follow -up reports are the same as those for the initial report.  
New information regarding an SAE that becomes available after the submission of the initial SAE Notification Form must b e reported by the Investigator to the Sponsor by completion of a 
SAE Follow-up Report F orm or through other written documentation (e.g., laboratory tests, 

miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 70 of 100 discharge summary, postmortem results).  Follow-up reports and/or written documentation must 
be provided to the Sponsor within 24 hours of the Investigator’s receipt  of the information. 
9.6 Post-Trial Adverse Events  
Any AE that occurs outside of the protocol-specified observation period or after the end of the trial but is considered to be caused by the investigational product must be reported to the Sponsor.   
9.7 Pregnancy Reporting and Follow-up 
Pregnancy in a female clinical trial participant is not an SAE per se.  Complications of such 
pregnancies, for example, spontaneous abortion, may qualify as an SAE and should be reported as an SAE even if they occur after the SAE reporting period has ended.   
The Investigator must notify the Sponsor via telephone or e- mail within 24 hours of awareness of 
a pregnancy in a study participant and must complete the Pregnancy Notification Form and 
submit it to the Sponsor within 2 working days of being notified.  The participant will not receive any further doses of their assigned study treatment.  The pregnancy must be followed to determine outcome, including spontaneous or voluntary termination, details of birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications .  This follow-up should occur even if the intended duration of safety follow-up for 
the trial has ended.  Information regarding the course of the pregnancy, including perinatal and postnatal offspring outcome up to 8 weeks of age should be reported as follow-up information on the Pregnancy Notification Form. While treatment will be discontinued for pregnant subjects, study observations may continue to evaluate study endpoints. 
Male study participants will be instructed to notify the Investigator if a female partner becomes 
pregnant during the study.  The Investigator must notify the Sponsor within 24 hours via telephone or e- mail and must complete the Pregnancy Notification Form and submit it to the 
Sponsor within 2 working days of being notified.  The Investigator should obtain informed consent from the subject ’s partner allowing the Investigator to obtain information regarding the 
pregnancy and its outcome.  If the subject ’s partner provides informed consent, the Investigator 
should follow the pregnancy until outcome as described above for female study participants and report the follow-up information on the Pregnancy Notification Form. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 71 of 100 9.8 Halting Rules  
Safety data will be reviewed on an ongoing basis by the Sponsor’s M edical Monitor.  While no 
formal stopping rules will be implemented, the Sponsor may suspend enrollment or terminate the 
study at any time for safety concerns.  
9.9 Emergency Sponsor Contact  
In a medical emergency (i .e., an event that requires immediate attention regarding operation of 
the clinical s tudy and/or the use of investigational drug), study site staff will apply appropriate 
medical intervention according to current standards of care, and contact the Medical Monitor or the designated Sponsor representative, as indicated in Section 1 of this protocol. 
10 TRIAL -SPECIFIC COMMITTEES 
No study- specifi c committee s will be used for this trial.  
11 STATISTICAL CONSIDERATIONS  
11.1 Statistical and Analytical Plans  
Final statistical analysis will be completed after the la st subject  completes or discontinues the 
study and the study database has been cleaned, verified, and locked.   
A statistical analysis plan (SAP) will be created prior to the unblinding or review of any data and 
prior to statistical analyses being performe d.  This document will provide a more technical and 
detailed description of the proposed data analysis methods and procedures. The results of the final analysis will be presented in the clinical study report appendices.  Any 
deviations from planned statist ical analyses will also be presented in the clinical study report.   
11.2 Study Hypotheses  
This early Phase 2 study is not designed to test any formal hypotheses. 
11.3 Analysis Sets 
Assignment of patients to analysis sets will be done prior to database lock. The following analysis sets will be defined: The Full Analysis Set (FAS), the Per Protocol Set (PPS), and the PK Analysis Set (PKAS).  
 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 72 of 100 11.3.1 Full Analyses Set (FAS)  
The FAS will include all randomized patients who received any amount of study drug 
(MRG -201 or placebo).  The treatment assignment for FAS will be as randomized for efficacy 
analyses and actual for safety analyses.  The FAS will be used for all efficacy and safety analyses. All patient data listings will use the FAS.  
11.3.2 Per Protocol Set (PPS) 
The PP S will consist of all participants who enrolled and completed the study, received all 
planned doses of study treatment, and completed all assessments necessary for the evaluation of the pharmacodynamic endpoints.  The PPS will be used for an additional analysis of eff icacy 
endpoints.  
11.3.3 PK Analysis Set (PKAS)  
The PKAS will be those patients in the FAS who have plasma concentration data available.  
11.4 Statistical Methods  
11.4.1 General Approach  
All descriptive statistical analyses will be performed using the most recently released and 
available SAS statistical software (version 9.3 or higher), unless otherwise noted.  For 
categorical variables, the number and percent of each category within a parameter will be presented.  For continuous variables, the sample size (n), mean, median, and standard deviation, as well as the minimum and maximum values, will be presented.  Missing data will not be imputed unless otherwise stated. 
11.4.2 Analysis of Demographics and Other Baseline Characteristics  
Demographics and other baseline disease characteris tics will be summarized by variable type  
across all subjects . 
11.4.3 Analysis of the Safety  Endpoint : Safety and Tolerability 
11.4.3.1 Adverse Events  
The analysis of the safety  endpoint will be based on AE incidence, physical examination 
findings, vital signs, ECG results and changes in clinical laboratory tests.  
Adverse events will be coded by preferred term and system organ class using the Medical 
Dictionary for Regulatory Activities  (MedDRA
®) and summary tables for all AEs will be 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 73 of 100 generated for the FAS.  Incidence rates  and percentages will be summarized for each preferred 
term and system organ class.  Additional summary tables will be generated for the following 
subsets:  subjects with SAEs, subjects with related AEs, subjects with severe (Grade 3 or 4) AEs, and subjects who discontinue due to AEs.  Depending on the doses achieved in this study, AEs may also be summarized by dose level.  Severity, investigator- attributed relationship to study 
treatment, and action taken will also be recorded. 
Concomitant medications will be coded using the World Health Organization Drug Dictionary 
(WHO -DD; 01 September 2017 or later version).  A dictionary listing of all unique concomitant 
medications used in the study will be provided. 
11.4.3.2 Physical Examination 
Clinically significant changes in vital signs and new findings on physical examination will be 
recorded as AEs.  Incidences of subjects with changes from normal physical examination 
findings at baseline to abnormal during the study may be generated. 
11.4.3.3 Laboratory Data 
All hematology, blood chemistry, and urinalysis results will be listed by subject  for each 
assessment and descriptive statistics may be tabulated for select criteria.  Changes from baseline 
and normal- abnormal shift tables  may be summarized.  
11.4.3.4 Twelve-lead ECG 
Information on ECGs will be presented in listings.  The incidence of subjects with changes from normal ECG findings at baseline to abnormal during the study will be generated as appropriate.  Summary of mean/median changes in ECG intervals may be generated on a data-driven basis.  
11.4.4 Analysis of Pharmacodynamic Endpoint s: Keloid Formation 
Pharmacodynamic analyses of keloid formation, including incidence of keloid formation, time to 
keloid formation, keloid volume and keloid severity, mVSS and POSAS scores, exploratory 
Patient Rep orted Outcomes, and other study assessments (e.g., antibody analyses) will be 
performed on a data-driven basis.   
Pharmacodynamic endpoints:  
• Proportion of confirmed  keloid formation at 24 weeks across subjects for treated vs. 
untreated lesions. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 74 of 100 Other pharm acodynamic endpoints:  
• Proportion of subjects with improved treated outcomes, which is defined as no confirmed 
keloid formation in the treated lesion vs. confirmed keloid formation in the untreated 
lesion , at 24 weeks over their untreated lesion. 
• Proportion of subjects forming confirmed keloids with MRG-201 treatment vs. placebo 
treatment at 12 weeks, 36 weeks, 52 weeks, and at the time of study withdrawal (if 
subjects do not complete the study). 
• Proportion of subjects with improved treated outcomes, which i s defined as no confirmed 
keloid formation in the treated lesion vs. confirmed keloid formation in the untreated lesion ,
 at 12 weeks, 36 weeks, 52 weeks, and at the time of study withdrawal (if subjects 
do not complete the study). 
• Proportion of subjects forming confirmed keloids regardless of treatment application . 
• Intra -patient and aggregated time from initial treatment on Day 1 to unconfirmed and 
confirmed keloid formation subjects in treated vs. untreated lesions. 
• Intra -patient and aggregated keloid volume between treated and untreated lesions at 
24 weeks, 52 weeks, and at the time of triamcinolone intervention (if applicable) for subjects in treated vs. untreated lesions. 
Exploratory endpoints: 
• Difference in mVSS and POSAS scores within subjects and acro ss subjects for treated vs. 
untreated lesions. 
• Other Patient Reported Outcomes . 
• Other exploratory biomarker assessments . 
A complete description of pharmacodynamic analyses will be included in the final clinical study 
report.  
11.4.5 Analysis of Exploratory Endpoin t: Pharmacokinetics  
PK parameters (C
max, Tmax, apparent half -life [t 1/2], apparent volume of distribution of the 
terminal phase [V z/F], apparent clearance [Cl/F], and AUC extrapolated to infinity [AUC 0-∞]) 
will be derived from plasma concentrations of MRG-201 using the actual sampling times.  Concentration data and all PK parameters will be listed by subject and summarized descriptively per dose.  Standard algorithms of the non-compartmental PK analysis program, WinNonLin software, will be used for these analyses.  
Individual plasma concentration versus actual time profiles for each subject and treatment, as well as the mean (± standard deviation) plasma concentration versus scheduled time profiles for each dose level, will be presented graphically.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 75 of 100 11.4.6 Planned I nterim Analyses  
Aggregated blinded interim analyses will be completed when at least 50% of the study subjects 
reach 12 weeks, 36 weeks and 52 weeks after study Day 1 . 
11.5 Sample Size Determination  
Approximately 12 subjects are anticipated for  enroll ment  in the first cohort  to attain 
approximately 10 subjects who complet e study participation through at least 24 week s.  A 
sample size of 10  subjects on active treatment is  considered  to be adequate for analysis of safety 
in this early Phase 2 study.  Additional subjects may be enrolled, up to a total of 16, if fewer than 10 subjects complete study participation through 24 weeks for reasons other than the safety or 
tolerability of study treatment, or if dosing is not completed per protocol for an individual subject for reasons other than the safety or tolerability of study treatment. 
The study is designed to start at an  expected effective dose for a 2 -week duration. The sponsor 
may enroll up to 5 additional cohorts of 12 to 16 subjects each (up to 80 total additional subjects) 
to assess the effect of a lower  dose or the effect of an increased dosing duration .  As with the first 
cohort, additional subjects may be enrolled in the additional cohorts, up to a total of 16 each, if 
fewer than 10 subjects in a given cohort co mplete the study through 24 weeks for reasons other 
than the safety or tolerability of study treatment, or if dosing is not completed per protocol for an individual subject for reasons other than the safety or tolerability of study treatment. 
11.6 Measures to Minimize Bias  
11.6.1 Randomization Procedures  
Subjects will be enrolled sequentially, starting with the first study cohort.  The treatment for each wound site will be randomized (left versus right), such that all subjects will receive both MRG -201 and placebo in a double-blinded fashion (Investigators and subjects will be blinded ). 
Subject  treatment assignments across all sites will be randomized using a central Interactive Web 
Response System.  
11.6.2 Evaluation of Success of Blinding  
Not applicable
 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 76 of 100 11.6.3 Breaking the Study Blind  
The blind may be broken for individual subjects for medical reasons if knowledge of the type of 
study treatment administered is required to guide appropriate treatment decisions.  If such unblinding is necessary, the Sponsor’s Medical Monitor must be consulted when possible. 
12 DATA HANDLING AND RECORD KEEPING  
12.1 Study Files and Patient Source Documents  
The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified.  These documents include the participant’s clinical source documents and I nvestigator’s Study Files .   
Participant  clinical source documents may include, but are not limited to, hospital/clinic records, 
physician’s and nurse’s notes, appointment book, original laboratory reports, ECG, radiograph, pathology and special assessment reports an d consultant letters.  
The investigator will ensure the Study Files are maintained , including the eCRFs and query 
forms, protocol/amendments, IRB and regulatory approvals with associated correspondence, signed ICFs, study treatment  records, staff curriculum vitae and authorization forms, all 
correspondence and other appropriate documents.  Such data shall be secured in order to prevent loss. 
The investigator will allow personnel authorized by the Sponsor access to all study data at any time.  
12.2 Data Collection Methods 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI.  The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  An eCRF must be completed for each person who signs informed consent, regardless of the duration of their trial participation.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  When making changes or corrections, cross out the original entry with a single line, and initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  Documents (including laboratory reports, hospital records subsequent to SAEs, etc.) transmitted to the CRO or the Sponsor should 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 77 of 100 include the assigned subject  identifier but should not include the subject ’s name in order to 
ensure confidentiality.  
Electronic CRFs will be provided for recording data for each participant enrolled in the study.  
Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and maintained in t he participant’s official 
electronic study record.  The Investigator should consult the eCRF Completion Guidelines for 
comprehensive instructions for completing the eCRF. 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and 
clinical laboratory data will be entered into Medidata Rave, a 21 Code of Federal Regulations 
(CFR ) Part 11 -compliant data capture system provided by Medidata Solutions, Inc.  The data 
system includes password protection and internal quality che cks, such as automatic range checks, 
to identify data that appear inconsistent, incomplete, or inaccurate.  Clinical data will be entered directly from the source documents. 
12.3 Retention of Records 
All clinical study documents must be retained by the investigator until at least 2 years after the last approval of a marketing application in an International Conference on Harmonization ( ICH) 
region and until there are no pending or contemplated marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified.  Investigators may need to retain documents longer if required by applicable regulatory requi rements or if requested by the Sponsor.  The investigator must notify the Sponsor prior to 
destroying any clinical study records.  Should the investigator wish to assign the study records to another party or move them to another location, the Sponsor must be notified in advance.  It is 
the responsibility of the Sponsor to inform the investigator when these documents no longer need to be retained.  
If the investigator cannot guarantee this archiving requirement at the study site for any or all of the document s, special arrangements must be made between the investigator and miRagen to 
securely store the documents in an off-site storage location so that they can be returned to the 
investigator in case of a regulatory audit.  Where source documents are required for the continued care of the subject , appropriate copies should be made for off- site storage.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 78 of 100 12.4 Protocol Deviations 
The investigator and the study site staff are responsible for ensuring the study is conducted in 
accordance with the schedule of procedures and assessment s described in this protocol and in 
accordance with Good Clinical Practice ( GCP ).  The site must use continuous vigilance to 
identify and report deviations within 24 hours of knowledge of their occurrence.  miRagen standard operating procedures will be followed for the reporting of study deviations. 
Intentional deviations from the protocol shall not be made without discussion with the Sponsor 
except in a medical emergency, when the intent is to reduce immediate risk to the subject .  In 
such cases, the Sponsor, CRO , the IRB and regulatory authorities, as appropriate, should be 
notified, in accordance with local requirements.  In all other cases, the nature of the deviation, the justification for the deviation, and prior written approval of the Sponsor must be documented.   
Changes to the protocol may be made only when a written substantial protocol amendment has been approved by the Sponsor and submitted to the IRB and applicable regulatory agencies in 
accordance with local requirements.  Appropriate approval(s) must be obtained before changes can be implemented.  
13 QUALITY CONTROL AND QUALITY ASSURANCE  
Quality Control procedures will be implemented beginning with the data entry system, and data 
quality control checks will be run on the database.  Any  missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution.  
miRagen  is responsible for ensuring the proper conduct of the study with regard to protocol 
adherence and validity of data recorded in the eCRFs by assigning  CRAs to each site.  The CRA 
is responsible for reviewing the eCRFs at regular intervals throughout the study, verifying adherence to the protocol, assuring completeness, consistency and accuracy of the data, reviewing study files and drug accountability.  The data will be verified against the original medical records and laboratory results as part of source document verification to ensure validity of the data.  The investigator’s responsibility is to ensure that any issues detected in the course of a monitoring visit are resolved.  
To ensure compliance with GCP and all applicable regulatory requirements, a quality assurance 
audit may be conduct ed by the Sponsor or the Sponsor’s designee .  Regulatory agencies may 
also conduct a regulatory inspection of this study.  Such audits/inspections can occur at any time during or after completion of the study.  If an audit or inspection occurs, the investigator and institution agree to allow the auditor/inspector direct access to all relevant documents and to 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 79 of 100 allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and 
any relevant issues.  
The investigator and study staff are responsible for maintaining a comprehensive and accurate 
filing system of all study -related documentation that will be suitable for inspection at any time 
by the Sponsor, its designees, and/or regulatory agencies (see Section 12.3).  In signing this 
protocol, the investigator understands and agrees to give access to the necessary documentation and files.  
14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
This Section 14 of the Clinical Trial Protocol is subject to the terms of the Clinical Trial 
Agreement between miRagen Therapeutics, Inc. and the study centers.  In the event of a discrepancy between the Clinical Trial Agreement and this Clinical Trial Protocol, the terms of the Clinical Trial Agreement shall control.  
14.1 Ethical Conduct of the Study  
This study will be conducted in compliance with the ICH GCP guidelines , United States  
regulations for the ethical conduct of clinical studies under 21 CFR Parts 50, 56 and 312, the 
Declaration of Helsinki, and with ICH guidelines regarding scientific integrity (E4, E8, E9 and E10).  This study will also adhere to all Food and Drug Administration ( FDA ), state and local 
regulatory requirements, and requirements for data protection. 
14.2 Institutional Review Board Review 
Before trial initiation, the investigator and institution must have written and dated approval from an accredited IRB for the study  protocol, written ICF, subject  recruitment procedures (e.g., 
advertisements), and any written information to be provided to subject s.  Any amendment to the 
protocol will require review and approval by the IRB before the changes are implemented to the study.  All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re-consented. 
Appropriate reports on the progress of the study will be made by the investigator to the IRB and 
the Sponsor in accordance with applicable regulations.  All correspondence with the IRB should 
be retained in the investigator’s Study File.  Copies of IRB approvals should be forwarded to 
miRagen  or its designee.    
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 80 of 100 14.3 Informed Consent  Process  
An ICF tem plate will be provided by the Sponsor to the investigator for submission to the IRB.  
Any site -specific changes to the ICF must be approved by the Sponsor prior to its submission to 
the IRB.  The ICF must be approved by the IRB prior to being presented to potential study 
participants.  
Individuals may agree to participate in the clinical trial only after the risks and possible benefits 
of their participation have been explained and extensively discussed.  The investigator will 
explain the purposes, procedures, and potential risks of the research study in terms suited to their comprehension, as well as their rights as a research subject .  Participants will have the 
opportunity to carefully review the written ICF, discuss the study with their surrogates, and ask questions prior to signing.  Written informed consent must be obtained from each study participant or his/her legally acceptable representative prior to conducting any study- related 
procedures. 
The investigator must use the most current IRB- approved ICF for documenting written consent.  
Each informed consent will be appropriately signed and dated by the subject or the subject ’s 
legally acceptable representative and  by the person obtaining consent.  The site must retain the 
original signed ICF and provide a copy to the subject . 
14.4 Confidentiality of Information  
Individual subject medical information obtained as a result of this study is considered 
confidential.  The investigator and the study center will adhere to all applicable laws relating to the protection of subject  information.  To assure that subject  confidentiality is maintained, 
subject  data will be identified only by a study-assigned number on any Sponsor forms, reports, 
publications, or in any other disclosures, except where required by law.  
All miR agen and delegated  personnel will handle subject  data in a confidential manner in 
accordance with applicable regulations governing clinical research .  Subject records will be 
inspected only in connection with this research project.  Information generated as a result of a 
subject ’s participation in this study may be disclosed to third parties for research , regulatory , and 
other purposes in any country as determined by miRagen Therapeutics, Inc .  However, subject s 
will not be individually identified but will be referred to by the study -assigned number. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 81 of 100 14.5 Future Use of Stored Specimens  
Data collected for this study will be analyzed and stored at miRagen or a designated laboratory .  
After the study is completed, the de- identified, archived data will be transmitted  to and stored at 
the miRagen or a delegated contract long -term storage vendor , for use by miRagen and its 
research collaborators .  Permission to analyze data and the future use of laboratory specimens 
will be included in the informed consent.  
With the participant’s approval and as approved by local IRBs, de- identified biological samples 
will be stored at miRagen or a designated vendor, and then a long-term storage vendor.  These 
samples could be used for future research performed by miRagen or its collabo rators .   
15 PUBLICATION POLICY 
Publication and/or disclosure of information or data related to this Clinical Trial  Protocol is 
subject to and governed by the Clinical Trial Agreement between miRagen Therapeutics, Inc. and the study center to which the Principal Investigator is a signatory.   
After conclusion of the study, investigators in this study may make oral presentations of study 
results or publish such results in scientific journals or other scholarly media without prior written approval from miRagen T herapeutics, Inc. , only after the following conditions have been met: 
• The results of the study in their entirety have been publicly disclosed by or with the consent of miRagen Therapeutics, Inc. in an abstract, manuscript or presentation forum; 
• The investigator has complied with the terms of the Clinical Trial Agreement and all 
requests from miRagen Therapeutics, Inc. to delete any references to its confidential 
information (other than study results); 
• The study has been completed at all study sites for at least 2 years.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 82 of 100 16 REFERENCE S 
1. Bartel DP. (2009) MicroRNAs: target recognition and regulatory functions. Cell 
136(2):215-233. 
2. Boon RA, Seeger T, Heydt S, et al. (2011) MicroRNA- 29 in aortic dilation: implications 
for aneurysm formation. Circ Res, 109(10):1115-1119. 
3. Brain O, Owens BM, Pichulik T, et al. (2013) The intracellular sensor NOD2 induces microRNA -29 expression in human dendritic cells to limit IL- 23 release. Immunity, 
39(3):521-536. 
4. Brown JJ and Bayat A. (2009) Genetic susceptibility to raised dermal s carring. Br J 
Dermatol, 161(1):8-18. 
5. Calin GA, Ferracin M, Cimmino A, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, 353(17):1793-1801. 
6. Cheng J, Wang Y, Wang D, et al. (2013) Identification of collagen 1 as a posttranscriptional target of miR -29b in skin fibroblasts: therapeutic implication for scar  
reduction. Am J Med Sci, 346(2):98-103. 
7. Cummins JM, He Y, Leary RJ, et al. (2006) The colorectal microRNAome. Proc Natl Acad Sci USA, 103(10):3687-3692. 
8. Cushing L, Kuang P, Lu J. (2015) The role of miR-29 in pulmonary fibrosis. Biochem Cell Biol, 93(2):109-118. 
9. English RS and Shenefelt PD. (1999) Keloids and hypertrophic scars. Dermatol Surg, 25(8):631-638. 
10. Fearmonti R, Bond J, Erdmann D, Levinson H. (2010) A review of scar scales and scar measuring devices. Eplasty 10:e43. 
11. Fort A, Borel C, Migliavacca E, et al . (2010) Regulation of fibrinogen production by 
microRNAs. Blood, 116(14):2608-2615. 
12. Friedman RC, Farh  KK, Burge CB,  et al. (2009) Most mammalian mRNAs are conserved 
targets of microRNAs. Genome Res 19(1):92-105. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 83 of 100 13. Garzon R, Garofalo M, Martelli MP, et al. (2008) Distinctive microRNA signature of 
acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA, 105(10):3945-3950. 
14. Garzon R, Heaphy CE, Havelange V, et al . (2009) MicroRNA 29b functions in acute 
myeloid leukemia. Blood, 114(26):5331-5341. 
15. Hu W, Dooley J, Chung SS, et al. (2015) miR- 29a maintains mouse hematopoietic stem 
cell self -renewal by regulatin g Dnmt3a. Blood, 125(14):2206-2216. 
16. Jiang H, Zhang G, Wu JH, et al. (2014) Diverse roles of miR-29 in cancer (review). Oncol Rep, 31(4):1509-1516. 
17. Kawashita Y, Jinnin M, Makino T, et al. (2011) Circulating miR-29a levels in patients with scleroderma spectr um disorder. J Dermatol Sci, 61(1):67-69. 
18. Li Z, Hassan MQ, Jafferji M, et al . (2009) Biological functions of miR-29b contribute to 
positive regulation of osteoblast differentiation. J Biol Chem, 284(23):15676-15684. 
19. Liang Y, Ridzon D, Wong L, et al. (2007) Characterization of microRNA expression profiles in normal human tissues. BMC Genomics, 8:166. 
20. Liston A, Papadopoulou AS, Danso- Abeam D, et al. (2012) MicroRNA-29 in the 
adaptive immune system: setting the threshold. Cell Mol Life Sci, 69(21):3533-3541. 
21. Liu Y, Taylor NE, Lu L, et al. (2010) Renal medullary microRNAs in Dahl salt- sensitive 
rats: miR -29b regulates several collagens and related genes. Hypertension, 55(4):974-
982. 
22. Ma F, Xu S, Liu X, et al. (2011) The microRNA miR-29 controls innate and adaptive 
immune responses to intracellular bacterial infection by targeting interferon -gamma. Nat 
Immunol, 12(9):861-869. 
23. Maegdefessel L, Azuma J, Toh R, et al. (2012) Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest, 122(2):497-506. 
24. Maurer B, Stanczyk J, Jungel A, et al. (2010) MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum, 62(6):1733-1743. 
25. Montgomery RL, Yu G, Latimer PA, et al. (2014) MicroRNA mimicry blocks pulmonary  
fibrosis. EMBO Mol Med, 6(10):1347-1356. 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 84 of 100 26. Nemeth AJ. (1993) Keloids and hypertrophic scars. J Dermatol Surg Oncol, 19(8):738-
746. 
27. Nguyen T, Kuo C, Nicholl MB, et al. (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor -related genes and disease outcome in 
cutaneous melanoma. Epigenetics, 6(3):388-394. 
28. Ott CE, Grunhagen J, Jager M, et al. (2011) MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3' UTR and coding- sequence 
binding sites. PLoS One, 6(1):e16250.  
29. Pandit KV, Milosevic J, Kaminski N. (2011) MicroRNAs in idiopathic pulmonary fibrosis. Transl Res, 157(4):191-199. 
30. Papadopoulou AS, Dooley J, Linterman MA, et al. (2012) The thymic epithelial microRNA network elevates the threshold for in fection -associated thymic involution via 
miR-29a mediated suppression of the IFN-alpha receptor. Nat Immunol, 13(2):181-187. 
31. Parker MW, Rossi D, Peterson M, et al. (2014) Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest, 124(4):1622-1635. 
32. Pekarsky Y, Koval A, Hallas C, et al. (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A, 97(7):3028-3033. 
33. Peng WJ, Tao JH, Mei B, et al. (2012) MicroRNA-29: a potential thera peutic target for 
systemic sclerosis. Expert Opin Ther Targets, 16(9):875-879. 
34. Qin W, Chung AC, Huang XR, et al. (2011) TGF- beta/Smad3 signaling promotes renal 
fibrosis by inhibiting miR -29. J Am Soc Nephrol, 22(8):1462-1474. 
35. Roderburg C, Urban GW, Bettermann K, et al. (2011) Micro- RNA profiling reveals a 
role for miR -29 in human and murine liver fibrosis. Hepatology, 53(1):209-218. 
36. Sekiya Y, Ogawa T, Yoshizato K, et al. (2011) Suppression of hepatic stellate cell activation by microRNA -29b. Biochem Biophys Res Commun, 412(1):74-79. 
37. Sengupta S, den Boon JA, Chen IH, et al. (2008) MicroRNA 29c is downregulated in nasopharyngeal carcinomas, up- regulating mRNAs encoding extracellular matrix 
proteins. Proc Natl Acad Sci U S A, 105(15):5874-5878. 
38. Sephel GC and Woodward SC. (2001). Repair, regeneration, and fibrosis. In E. Rubin (Ed.), Rubin’s Pathology (pp. 84- 117). Baltimore: Lippincott, Williams & Wilkins.  
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidentia l  Page 85 of 100 39. Smith KM, Guerau-de-Arellano M, Costinean S, et al. (2012) miR-29ab1 deficiency 
identifies a negative feedb ack loop controlling Th1 bias that is dysregulated in multiple 
sclerosis. J Immunol, 189(4):1567-1576. 
40. Steiner DF, Thomas MF, Hu JK, et al. (2011) MicroRNA-29 regulates T- box 
transcription factors and interferon-gamma production in helper T cells. Immunity, 35(2):169-181. 
41. Teofoli P, Barduagni S, Ribuffo M, et al. (1999) Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci, 22(1):31-37. 
42. Thomson JM, Parker J, Perou CM, et al. (2004) A custom microarray pla tform for 
analysis of microRNA gene expression. Nat Methods, 1(1):47-53. 
43. van Rooij E, Sutherland LB, Thatcher JE, et al . (2008) Dysregulation of microRNAs after 
myocardial infarction reveals a role of miR -29 in cardiac fibrosis. Proc Natl Acad Sci 
USA, 105(35):13027-13032. 
44. Villarreal G, Oh DJ, Kang MH, et al. (2011) Coordinated regulation of extracellular matrix synthesis by the microRNA -29 family in the trabecular meshwork. Invest 
Ophthalmol Vis Sci, 52(6):3391-3397. 
45. Wang H, Chiu M, Xie Z, et al. (2012) Sy nthetic microRNA cassette dosing: 
pharmacokinetics, tissue distribution and bioactivity. Mol Pharm, 9(6):1638-1644. 
46. Xiao J, Meng XM, Huang XR, et al. (2012) miR-29 inhibits bleomycin-induced pulmonary fibrosis in Mice. Mol Ther, 20(6):1251-1260. 
47. Xiong Y, Fang JH, Yun JP, et al. (2010) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology, 51(3):836-845. 
48. Xu H, Cheung IY, Guo HF, et al . (2009) MicroRNA miR-29 modulates expression of 
immunoinhibitory molecul e B7-H3: potential implications for immune based therapy of 
human solid tumors. Cancer Res, 69(15):6275-6281. 
49. Yanaihara N, Caplen N, Bowman E, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3):189-198. 
50. Zhang Y, Wu L, Wang Y, et al. (2012) Protective role of estrogen- induced miRNA -29 
expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem, 287(18):14851-14862. 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidentia l Page 86 of 100 51.Zhang G-Y, Wu L-C, Liao T, et al. (2016) A novel regulatory function for m iR-29a in
keloid fibrogenesis. Clin Exp Dermatol, 41: 341-345.
52.Zhao JJ, Lin J, Lwin T, et al. (2010) microRNA expression profile and identification of
miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell
lymphoma. Blood, 115(13):2630-2639.
53. Zhu H, Li Y, Qu S, et al. (2012) MicroRNA expression abnormalities in limited
cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol, 32(3):514-522.
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Proprietar y and Confidential  Page 87 of 100 17 LIST OF APPENDICES 
Appendix A. Schedule of Events for First Cycle of Dosing with MRG-201 and Placebo with 6  
Doses at Initial Treatment Cycle............................................................................88 
Appendix B. Schedule of Events for Second Cycle of Dosing with MRG-201 and/or Placebo (6 
Doses after Initial Treatment Cycle) ......................................................................90 
Appendix C. Schedule of Events for Single Cycle of Dosing with MRG-201 and/or Placebo (12 
Doses for Initial Treatment Cycle) ........................................................................92 
Appendix D. Modified Vancouver Scar Scale ............................................................................94 
Appendix E. The Patient and Observer Scar Assessment Scale (POSAS) v 2.0 EN ..................95 
Appendix F. The Dermatology Life Quality Index (DLQI) .......................................................97 
Appendix G. Estimated Blood Volumes for 6-dose Regimen at Initial Treatment Cycle  ..........98 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 88 of 100 Appendix A. Schedule of Events  for First Cycle of Dosing with MRG -201 and Placebo with 6 Doses at Initial Treatment Cycle  
Study Procedure  Screening  
(up to 28 -
day 
window)  Day 1 a Day 2 Days 3 
and 5  Day 8 Day 10  Day 12  Day 13  Day 19 
(±2 days)  Day 29 
(±3 days)  Days 57, 113, 
141, 197, 225, 
281, 309, 337 
(±7 days)  Day 85  
(±7 days)  Days 169 
and 253  
(±7 days)  Day 365/  
End of 
Study  
(± 7 days) o 
Informed Consent  X 
Medical History  X 
Inclusion/Exclusion Criteria  X X 
Vital Signs  X X X X X X X X X X X X X X 
Physical Examination b X X X X X X X X X 
Weight X X X X 
HIV, Hepatitis B, Hepatitis C  X 
FSH c  X 
Pregnancy Test d X X X X X X 
12-lead ECG eX X X X 
Laboratory Assessments f X X X X X X X X X X 
Serum Collection for Antibody 
Analysis  X X X X X (D ay 
169 only)  
6-mm Punch Biopsies gX 
Study Treatment Injections h X X X X X 
Physician Assessments for Keloid 
Formation  and Volume   X X X X X X 
Modified Vancouver Scar Scale 
and POSAS  X X X X X X X X 
DLQI  X X X (Day 
169 only)  X 
Adverse Events i X X X X X X X X X X X X X 
Prior and Concomitant Medications
 j X X X X X X X X X X X X X X 
PK Sample Collection X k X l X k X l 
Urine Sample Collection for PK mX X X X 
Photography of Biopsy Sites n X X X X X 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 89 of 100 Abbreviations: AE = adverse event; aPTT = activated partial thromboplastin time; ECG = electrocardiogram; eCRF = electronic case report form; FSH = follicle -stimulating 
hormone; HIV = human i mmunodeficiency virus; INR = international normalized ratio;  PK = pharmacokinetic(s); PT = prothrombin time; SAE = serious adverse event  
a)Day 1 refers to the first dosing day for the first double -blind active treatment  period .
b)Complete physical examination at screening and Day 1; brief physical examination at all other time points .
c)Only for women who are not surgically sterile as confirmation of menopause .
d)Serum pregnancy test at screening and urine pregnancy test s on Days 1, 12, 29, 85  and at the end of the study for female subjects .
e)Performed at screening, predose on Day 1, on Day 2 (approximately 24 hours after Day 1 dosing), and predose on Day 12.
f)Hematology, clinical chemistry, and urinalysis (including microscopy) will be collected predose  as indicated in the protocol.  Laboratory assessments do not need to be
performed on Day 1 if screening laboratory measurements were performed  within 3 days prior to Day 1.
g)6-mm punch biopsy to create two excisional wounds (one treated with MRG -201 and one treated with  placebo on Day 1) as described in the Study Manual .
h)Subject s will receive intradermal injection s of MRG -201 and intradermal injections of placebo at each time point.  Refer to the Study Manual  for detailed instructions on
intradermal injections – Biopsy  Site Selection, Injection, and Brief Photography Instructions .
i)All AEs, including SAEs, will be recorded from the time of administration of the first dose of study treatment  on Day 1 until 30 days after the last dose of study treatment  or
the end of study  visit, whichever occurs last.  Treatment -related AEs ongoing at the follow -up visit should be followed to resolution or until the investigator considers them
“chronic” or “stable.”
j)All medications (including over -the-counter medicines, herbal treatments, supplements, and vitamins) administered 30 days before the first administration of study treatment
(Day 1) until the e nd of study (Day 365) will be recorded on the eCRF .
k)On Day 1  and Day 12, plasma for PK will be drawn at 1 hour ( ± 10 minutes), 2 hours ( ± 15 minutes), and 3 hours ( ± 15 minutes) after injection .
l)On Day 2  and Day 13, p lasma for PK will be drawn 24 (± 4) hours after Day 1 /12 dosing.
m)A voided urine sample will be collected on Day 1 and 12 predose and  3 hours post dose, Day 2 and 13 (24 ± 4 hours  after Day 1 /12 dosing).
n)Photography of biopsy  wound sites will be performed post -biopsy on Day 1. In addition to the indicated time points, wound sites will be photographed at the time the
investigator suspects a keloid may be forming, at the time of observation of an unconfirmed keloid, and at the time of keloid c onfirm ation  (predose if coinciding with a dosing
day).  Refer to the Study Manual for detailed instructions .
o)End-of-study assessments will be performed  on Day 365 or at the  final visit for subjec ts who discontinue treatment early (if the subject has not withdrawn consent) .
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidential  Page 90 of 100 Appendix B. Schedule of Events for Second Cycle of Dosing with MRG -201 and/or Placebo (6 Doses after Initial Treatment 
Cycle)  
Study Procedure  Mon thly 
Visit for 
Keloid 
Identification Day 1 a Day 2 Days 3 
and 5  Day 8 Day 10  Day 12  Day 19  
(±2 days)  Day 29  
(±3 days)  Subsequent 
Visits, Every 4 
Weeks  
(±7 days)  k Day 365 / 
End of Study  
(± 7 days) l 
Keloid Identification  X         
See 
Appendix  A for a 
complete list of 
time points and 
assessments to 
be performed  See 
Appendix  A for 
a complete list of 
assessments to 
be performed  Vital Signs   X X X X X X X X 
Physical Examination b  X   X  X X X 
Weight   X     X   
Pregnancy Test c  X       X 
12-lead ECG d   X X    X   
Laboratory Assessments e  X X  X    X 
Study Treatment Injections f  X  X X X X   
Physician Assessments for Keloid 
Formation  and Volume  g  X X X X X X X X 
Modifi ed Vancouver Scar Scale and 
POSAS   X   X  X X X 
Adverse Events h  X X X X X X X X 
Concomitant Medications i  X X X X X X X X 
Photography of Biopsy Sites j  X       X 
Abbreviations: AE = adverse event; aPTT = activated partial thromboplastin tim e; ECG = electrocardiogram; eCRF = electronic case report form; INR = international normalized 
ratio; PT = prothrombin time; SAE = serious adverse event  
a) Day 1 refers to the first dosing day for the second double -blind active treatment period.  Procedures required for the regularly scheduled visit day must also be performed.  
b) Complete physical examination on Day 1; brief physical examination at all other time points.  
c) Urine pregnancy test on Days 1 and 29 and at the end of the study for female subjects.  
d) Perform ed on Day 1 predose , on Day 2 (approximately 24 hours after Day 1 dosing), and predose on Day 12.  
e) Hematology, clinical chemistry, and urinalysis (including microscopy) will be collected predose  as indicated in the protocol.  
f) Subjects will receive intradermal injections of MRG -201 and/or placebo at each time point, depending on the location of the suspected keloid.  Refer to the Study Manual for 
detailed instructions on intradermal injections – Biopsy Site Selection, Injection, and Brief Photography Instructions. 
g) Physician Assessments will be completed predose on dosing visit days.  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final  
16 March 2018  
Prop rietary and Confidential  Page 91 of 100 h)All AEs, including SAEs, will be recorded from the time of administration of the first dose of study treatment on Day 1 until 30  days after the last dose of study treatment o r
the end of study visit, whichever occurs last.  Treatment -related AEs ongoing at the follow -up visit should be followed to resolution or until the investigator considers them
“chronic” or “stable.”
i)All medications (including over -the-counter medicines, herbal t reatments, supplements, and vitamins) administered 30 days before the first administration of study treatment
(Day 1) until the end of study (Day 365) will be recorded on the eCRF.
j)Photography of biopsy sites will be performed predose on Day 1.  Refer to t he Study  Manual for detailed instructions.
k)Following the visit that occurs 29 days after the start of the second cycle of study dosing , re-treated biopsy sites will be followed according to the first cycle  visit schedule
(Appendix  A).
l)End-of-study assessments will be  performed on Day 365 or at the final visit for subjects who discontinue treatment early (if the subject has not withdrawn conse nt).
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidential  Page 92 of 100 Appendix C. Schedule of Events  for Single Cycle of Dosing with MRG -201 and/or Placebo  (12 Doses for Initial Treatment 
Cycle)  
Study Procedure  Screening  
(up to 28 -
day 
window)  Day 1 a Day 2 Days 3 , 
5, 10, 
12, 17, 
19, and 
24 Day 8 Days 15 
and 22  Day 26  Day 27  Day 2 9  
(±1 day)  Day 36  
(±2 days)  Days 57, 113,  
141, 197, 225, 
281, 309, 337 
(±7 days)  Day 85  
(±7 days)  Days 169 
and 253  
(±7 days)  Day 365/  
End of 
Study  
(± 7 days) o 
Informed Consent  X              
Medical History  X              
Inclusion/Exclusion Criteria  X X             
Vital Signs  X X X X X X X X X X X X X X 
Physical Examination b X X   X X   X   X X X 
Weight  X        X   X  X 
HIV, Hepatitis B, Hepatitis C  X              
FSH c  X              
Pregnancy Test d X X       X   X  X 
12-lead ECG e  X X X      X      
Laboratory Assessments f X X X  X X   X   X X X 
Serum Collection for Antibody 
Analysis   X    X (Day 
15 only)    X   X X (Day  
169 only)   
6-mm Punch Biopsies g  X             
Study Treatment Injection h  X  X X X X        
Physician Assessments for Keloid 
Formation and Volume      X X   X  X X X X 
Modified Vancouver Scar Scale 
and POSAS      X X   X  X X X X 
DLQI   X   X        X (Day 
169 only)  X 
Adverse Events i  X X X X X X X X X X X X X 
Prior and Concomitant Medications
 j X X X X X X X X X X X X X X 
PK Sample Collection   X k X l    X k X l       
Urine S ample Col lection  for PK m  X X    X X       
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
  Version 1.0, Final  
 16 March 2018  
 
 Proprietary and Confidential  Page 93 of 100 Photography of Biopsy Sites n  X       X   X X X 
Abbreviations: AE = adverse event; aPTT = activated partial thromboplastin time; ECG = electrocardiogram; eCRF = electronic case report form; FSH = follicle -stimulating 
hormone; HIV = human immunodeficiency virus; INR = international normalized ratio; PK = pharmacokinetic(s); PT = prothrombin time; SAE = serious adverse event  
a) Day 1 refers to the first dosing d ay for the first double -blind active treatment period.  
b) Complete physical examination at screening and Day 1; brief physical examination at all other time points . 
c) Only for women who are not surgically sterile as confirmation of menopause.  
d) Serum pregnancy te st at screening and urine pregnancy tests on Days 1 29 , 85 and at the end of the study for female subjects.  
e) Performed at screening, predose on Day 1, on Day 2 (approximately 24 hours after Day 1 dosing), and predose on Day 29. 
f) Hematology, clinical chemistr y, and urinalysis (including microscopy) will be collected predose  as indicated in the protocol.  Laboratory assessments do not need to be 
performed on Day 1 if screening laboratory measurements were performed within 3 days prior to Day 1.  
g) 6-mm punch biops y to create two excisional wounds (one treated with MRG -201 and one treated with placebo on Day 1) as described in the Study Manual .   
h) Subject s will receive intradermal injections of MRG -201 and intradermal injections of placebo at each time point.  Refer to the Study Manual  for detailed instructions on 
intradermal injections – Biopsy Site Selection, Injection, and Brief Photography Instructions.  
i) All AEs, including SAEs, will be recorded from the time of administration of the first dose of study treatment  on Day 1 until 30 days after the last dose of study treatment or 
the end of study visit, whichever occurs last.  Treatment -related AEs ongoing at the follow -up visit should be followed to resolution or until the investigator considers them 
“chronic” or “stable.” 
j) All medications (including over -the-counter medicines, herbal treatments, supplements, and vitamins) administered 30 days before the first administration of study treatment 
(Day 1) until the end of study (Day 365) will be recorded on the eCRF.  
k) On Day  1 and Day 26, plasma for PK will be drawn at 1 hour ( ± 10 minutes), 2 hours ( ± 15 minutes), and 3 hours ( ± 15 minutes) after injection.  
l) On Day 2  and Day 27, plasma for PK will be drawn 24 (± 4) hours after Day 1 /Day 26  dosing.  
m) A voided urine sample will b e collected on Day 1 and 26  predose and  3 hours post dose, and Day 2 and 27 (24 ± 4 hours after Day 1 /26 dosing).  
n) Photography of biopsy  wound sites will be performed post -biopsy on Day 1. In addition to the indicated time points, wound sites will be photogr aphed at the time the 
investigator suspects a keloid may be forming, at the time of observation of an unconfirmed keloid, and at the time of keloid confirmation  (predose if coinciding with a dosing 
day).  Refer to the Study Manual for detailed instructions . 
o) End-of-study assessments will be performed on Day 365 or at the  final visit for subjects who discontinue treatment early (if the subject has not withdrawn consent) . 
 
 
 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final 
 16 March 2018  
Prop rietary and Confidential  Page 94 of 100 Appendix D. Modified Vancouver Scar Scale  
Scar Charac teristic  Score 
Vascularity  Normal  0 
Pink 1 
Red 2 
Purple  3 
Pliability  Normal  0 
Supple  1 
Yielding  2 
Firm  3 
Ropes  4 
Contracture  5 
Height  Flat 0 
<2 mm  1 
2-5 mm 2 
>5 mm 3 
Total score  11 
Derived from : Fearmonti R, Bond J, Erdmann D, Le vinson H. (2010) A review of scar scales and scar measuring 
devices. Eplasty 10:e43.  
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final 
 16 March 2018  
Prop rietary and Confidential  Page 95 of 100 Appendix E. The Patient and Observer Scar Assessment Scale (POSAS) v 2.0 EN  

miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final 
  16 March 2018  
 
 Proprietary and Confidential   Page 96 of 100 
 
 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final 
  16 March 2018  
 
 Proprietary and Confidential   Page 97 of 100 Appendix F. The Dermatolo gy Life Quality Index (DLQI) 
 
 
miRagen Therapeutics , Inc.  Protocol No. MRG 201-30-201 
Version 1.0, Final 
 16 March 2018  
Propr ietary and Confidential  Page 98 of 100 Appendix G. Estimated Blood Volumes for 6 -dose Regimen at Initial Treatment Cycle 
Study Day  Time Point  Test Draw Amount (mL)  
Screening  
(28-day 
window)  Hematology  4 
Chemistry  8.5 
Serum Pregnancy  (with chemistry)  
HIV, Hep B, Hep C  (with chemistry)  
Total Screening  12.5 
Day 1 Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
PK (1 hour)  5 
PK (2 hours)  5 
PK (3 hours)  5 
Total Day 1 32.5 
Day 2  24 hours following Day 1 dose  Hematology  4 
Chemistry  8.5 
PK 5 
Total Day 2  17.5 
Day 8  Hematology  4 
Chemistry  8.5 
Total Day 8  12.5 
Day 12  Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
PK (1 hour)  5 
PK (2 hours)  5 
PK (3 hours)  5 
Total Day 12  32.5 
Day 19  Hematology  4 
Chem istry 8.5 
Total Day 5  12.5 
Day 29  Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
Total Day 29  17.5 
Day 85  Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
Total Day 85  17.5 
Day 169  Hematology  4 
Chemistry  8.5 
Antibody Ser um Sample  5 
Total Day 169  17.5 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final 
  16 March 2018  
 
 Proprietary and Confidential   Page 99 of 100 Study Day  Time Point  Test Draw Amount (mL)  
Day 253  Hematology  4 
Chemistry  8.5 
Total Day 253 12.5 
Day 365  / EOS   Hematology  4 
Chemistry  8.5 
Total Day 365  / EOS  12.5 
Study total (not including repeats or unscheduled samples)  197.5* 
• Up to an additional 50 mL of blood will be drawn if a second cycle of dosing is required (6 doses after 
initial treatment cycle)  
 
Estimated Blood Volumes for 12- dose Regimen at Initial Treatment Cycle  
Study Day  Time Point  Test Draw Amount (mL)  
Screening  
(28-day 
window)   Hemat ology  4 
Chemistry  8.5 
Serum Pregnancy  (with chemistry)  
HIV, Hep B, Hep C  (with chemistry)  
Total Screening  12.5 
Day 1   Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
PK (1 hour)  5 
PK (2 hours)  5 
PK (3 hours)  5 
Total Day 1  32.5 
Day 2  24 hours following Day 1 dose  Hematology  4 
Chemistry  8.5 
PK 5 
Total Day 2  17.5 
Day 8   Hematology  4 
Chemistry  8.5 
Total Day 8  12.5 
Day 15   Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
Total Day 15  17.5 
Day 22   Hematol ogy 4 
Chemistry  8.5 
Total Day 22  12.5 
Day 26   PK (1 hour)  5 
PK (2 hours)  5 
PK (3 hours)  5 
Total Day 26  15 
miRagen Therapeutics , Inc.   Protocol No. MRG 201-30-201 
  Version 1.0, Final 
  16 March 2018  
 
 Proprietary and Confidential   Page 100 of 100 Study Day  Time Point  Test Draw Amount (mL)  
Day 27  24 hours after Day 26 dose  PK 5 
Total Day 27  5 
Day 29   Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
Total Day 2 9 17.5 
Day 85   Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
Total Day 85  17.5 
Day 169  Hematology  4 
Chemistry  8.5 
Antibody Serum Sample  5 
Total Day 169  17.5 
Day 253  Hematology  4 
Chemistry  8.5 
Total Day 253 12.5 
Day 365  / EOS   Hematology  4 
Chemistry  8.5 
Total Day 365  / EOS  12.5 
Study total (not including repeats or unscheduled samples)  202.5 
 